<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006678.pub2" GROUP_ID="CHILDCA" ID="707606060616013471" MERGED_FROM="" MODIFIED="2014-12-18 11:11:05 +0000" MODIFIED_BY="Jos Noorman" REVIEW_NO="003" REVMAN_SUB_VERSION="5.2.11 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2014-12-18 11:11:05 +0000" MODIFIED_BY="Jos Noorman">
<TITLE>Chemotherapy for children with medulloblastoma</TITLE>
<CONTACT MODIFIED="2014-12-18 11:11:05 +0000" MODIFIED_BY="Jos Noorman"><PERSON ID="276941F182E26AA200831C198DA7A769" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Erna</FIRST_NAME><MIDDLE_INITIALS>MC</MIDDLE_INITIALS><LAST_NAME>Michiels</LAST_NAME><POSITION>Paediatric Oncologist</POSITION><EMAIL_1>e.michiels@erasmusmc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Erasmus MC - Sophia Children's Hospital</ORGANISATION><ADDRESS_1>PO Box 2060</ADDRESS_1><CITY>Rotterdam</CITY><ZIP>3000 CB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 10 463 6786</PHONE_1><PHONE_2>+31 10 463 6691</PHONE_2><FAX_1>+31 10 463 6801</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-12-18 11:11:05 +0000" MODIFIED_BY="Jos Noorman"><PERSON ID="276941F182E26AA200831C198DA7A769" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Erna</FIRST_NAME><MIDDLE_INITIALS>MC</MIDDLE_INITIALS><LAST_NAME>Michiels</LAST_NAME><POSITION>Paediatric Oncologist</POSITION><EMAIL_1>e.michiels@erasmusmc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Erasmus MC - Sophia Children's Hospital</ORGANISATION><ADDRESS_1>PO Box 2060</ADDRESS_1><CITY>Rotterdam</CITY><ZIP>3000 CB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 10 463 6786</PHONE_1><PHONE_2>+31 10 463 6691</PHONE_2><FAX_1>+31 10 463 6801</FAX_1></ADDRESS></PERSON><PERSON ID="B052A09D82E26AA200D5E26B5928293F" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Antoinette</FIRST_NAME><MIDDLE_INITIALS>YN</MIDDLE_INITIALS><LAST_NAME>Schouten-Van Meeteren</LAST_NAME><POSITION>Paediatric Oncologist</POSITION><EMAIL_1>a.y.n.schouten@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5663050</PHONE_1><FAX_1>+31 20 5669690</FAX_1></ADDRESS></PERSON><PERSON ID="B052A22382E26AA200D5E26BD0448571" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>François</FIRST_NAME><LAST_NAME>Doz</LAST_NAME><EMAIL_1>francois.doz@curie.net</EMAIL_1><ADDRESS><DEPARTMENT>Paediatric Oncology</DEPARTMENT><ORGANISATION>Institut Curie</ORGANISATION><ADDRESS_1>26 rue d'Ulm</ADDRESS_1><CITY>Paris</CITY><ZIP>75231</ZIP><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 1 44324555</PHONE_1><FAX_1>+33 1 53104005</FAX_1></ADDRESS></PERSON><PERSON ID="z1304091452214197776118233245631" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Geert</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Janssens</LAST_NAME><POSITION>Radiation Oncologist</POSITION><EMAIL_1>G.Janssens@rther.umcn.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Radiation Oncology</DEPARTMENT><ORGANISATION>Radboud University Nijmegen Medical Centre</ORGANISATION><ADDRESS_1>PO Box 9101</ADDRESS_1><CITY>Nijmegen</CITY><ZIP>6500 HB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31-24-3614515</PHONE_1><FAX_1>+31-24-3610792</FAX_1></ADDRESS></PERSON><PERSON ID="13729" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elvira</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>van Dalen</LAST_NAME><EMAIL_1>e.c.vandalen@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660 (room TKsO-247)</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5665697</PHONE_1><FAX_1>+ 31 20 5669021</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-10-20 10:27:38 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="6" MONTH="8" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="6" MONTH="8" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="7" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="12" YEAR="2014"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2009-10-07 10:59:59 +0200" MODIFIED_BY="[Empty name]"/>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2009-10-07 15:13:27 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2009-10-07 15:13:27 +0200" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Dutch Cochrane Centre</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2009-10-07 15:13:27 +0200" MODIFIED_BY="[Empty name]">
<NAME>Stichting Kinderen Kankervrij (KIKA)</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-11-17 12:04:46 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-11-17 11:19:09 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-12-08 14:03:10 +0100" MODIFIED_BY="[Empty name]">Chemotherapy for children with medulloblastoma</TITLE>
<SUMMARY_BODY MODIFIED="2014-11-17 11:19:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>Medulloblastoma is one of the most common malignant brain tumours in children. Chemotherapy is used to improve survival and diminish potential radiotherapy-induced side effects. The reduction of radiotherapy-induced side effects is achieved in very young children by not treating them with radiotherapy and in older children by diminishing the craniospinal radiotherapy (radiotherapy applied to the brain and spinal cord) dose and by reducing the boost volume to the tumour bed only instead of the whole posterior fossa (part of the brain). A well-informed decision on the use of chemotherapy in the treatment of medulloblastoma in children should be based on high-quality evidence on both the effectiveness against the tumour and side effects.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We searched databases for randomised trials (studies where participants are allocated to one of two or more treatment groups in a random manner) evaluating the effectiveness of treatment including chemotherapy versus treatment not including chemotherapy (seven available studies) and on randomised studies evaluating the effectiveness of standard-dose radiotherapy without chemotherapy versus reduced-dose radiotherapy plus chemotherapy (one available study) in children (aged 0 to 21 years). The evidence is current to August 2013.</P>
<P>
<B>Key results and quality of the evidence</B>
</P>
<P>Based on the evidence identified in this systematic review a benefit of chemotherapy cannot be excluded, but at this moment we are unable to draw a definitive conclusion to favour treatment with or without chemotherapy. Even though randomised studies are the highest level of evidence, it should be recognised that data from non-randomised studies were available, for example on the use of chemotherapy only in very young children. The results are promising for children without metastatic disease. For treatment with standard-dose radiotherapy without chemotherapy as compared with reduced-dose radiotherapy with chemotherapy, we also cannot make definitive recommendations. More high-quality research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-11-17 11:34:32 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-11-12 22:07:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Post-surgical radiotherapy (RT) in combination with chemotherapy is considered as standard of care for medulloblastoma in children. Chemotherapy has been introduced to improve survival and to reduce RT-induced adverse effects. Reduction of RT-induced adverse effects was achieved by deleting (craniospinal) RT in very young children and by diminishing the dose and field to the craniospinal axis and reducing the boost volume to the tumour bed in older children.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-11-12 22:07:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Primary objectives: 1. to determine the event-free survival/disease-free survival (EFS/DFS) and overall survival (OS) in children with medulloblastoma receiving chemotherapy as a part of their primary treatment, as compared with children not receiving chemotherapy as part of their primary treatment; 2. to determine EFS/DFS and OS in children with medulloblastoma receiving standard-dose RT without chemotherapy, as compared with children receiving reduced-dose RT with chemotherapy as their primary treatment.</P>
<P>Secondary objectives: to determine possible adverse effects of chemotherapy and RT, including long-term adverse effects and effects on quality of life.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-11-12 22:07:29 +0100" MODIFIED_BY="Anne Lawson">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2013, Issue 7), MEDLINE/PubMed (1966 to August 2013) and EMBASE/Ovid (1980 to August 2013). In addition, we searched reference lists of relevant articles, conference proceedings and ongoing trial databases (August 2013).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-11-12 22:07:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trials (RCTs) evaluating the above treatments in children (aged 0 to 21 years) with medulloblastoma.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-11-12 22:07:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Two review authors independently performed study selection, data extraction and risk of bias assessment. We performed analyses according to the guidelines of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>. Where possible, we pooled results.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-11-12 22:05:42 +0100" MODIFIED_BY="Anne Lawson">
<P>The search identified seven RCTs, including 1080 children, evaluating treatment including chemotherapy and treatment not including chemotherapy. The meta-analysis of EFS/DFS not including disease progression during therapy as an event in the definition showed a difference in favour of treatment including chemotherapy (hazard ratio (HR) 0.70; 95% confidence interval (CI) 0.54 to 0.91; P value = 0.007; 2 studies; 465 children). However, not including disease progression as an event might not be optimal and the finding was not confirmed in the meta-analysis of EFS/DFS including disease progression during therapy as an event in the definition (HR 1.02; 95% CI 0.70 to 1.47; P value = 0.93; 2 studies; 300 children). Two individual studies using unclear or other definitions of EFS/DFS also showed no clear evidence of difference between treatment arms (one study with unclear definition of DFS: HR 1.67; 95% CI 0.59 to 4.71; P value = 0.34; 48 children; one study with other definition of EFS: HR 0.84; 95% CI 0.58 to 1.21; P value = 0.34; 233 children). In addition, it should be noted that in one of the studies not including disease progression as an event, the difference in DFS only reached statistical significance while the study was running, but due to late relapses in the chemotherapy arm, this significance was no longer evident with longer follow-up. There was no clear evidence of difference in OS between treatment arms (HR 1.06; 95% CI 0.67 to 1.67; P value = 0.80; 4 studies; 332 children). Out of eight reported adverse effects, of which seven were reported in one study, two (severe infections and fever/neutropenia) showed a difference in favour of treatment not including chemotherapy (severe infections: risk ratio (RR) 5.64; 95% CI 1.28 to 24.91; P value = 0.02; fever/neutropenia: RR not calculable; Fisher's exact P value = 0.01). There was no clear evidence of a difference between treatment arms for other adverse effects (acute alopecia: RR 1.00; 95% CI 0.92 to 1.08; P value = 1.00; reduction in intelligence quotient: RR 0.78; 95% CI 0.46 to 1.30; P value = 0.34; secondary malignancies: Fisher's exact P value = 0.5; haematological toxicity: RR 0.54; 95% CI 0.20 to 1.45; P value = 0.22; hepatotoxicity: Fisher's exact P value = 1.00; treatment-related mortality: RR 2.37; 95% CI 0.43 to 12.98; P value = 0.32; 3 studies). Quality of life was not evaluated. In individual studies, the results in subgroups (i.e. younger/older children and high-risk/non-high-risk children) were not univocal.</P>
<P>The search found one RCT comparing standard-dose RT with reduced-dose RT plus chemotherapy. There was no clear evidence of a difference in EFS/DFS between groups (HR 1.54; 95% CI 0.81 to 2.94; P value = 0.19; 76 children). The RCT did not evaluate other outcomes and subgroups.</P>
<P>The presence of bias could not be ruled out in any of the studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-11-17 11:34:32 +0100" MODIFIED_BY="[Empty name]">
<P>Based on the evidence identified in this systematic review, a benefit of chemotherapy cannot be excluded, but at this moment we are unable to draw a definitive conclusion regarding treatment with or without chemotherapy. Treatment results must be viewed in the context of the complete therapy (e.g. the effect of surgery and craniospinal RT), and the different chemotherapy protocols used. This systematic review only allowed a conclusion on the concept of treatment, not on the best strategy regarding specific chemotherapeutic agents and radiation dose. Several factors complicated the interpretation of results including the long time span between studies with important changes in treatment in the meantime. 'No evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. The fact that no significant differences between treatment arms were identified could, besides the earlier mentioned reasons, also be the result of low power or too short a follow-up period. Even though RCTs are the highest level of evidence, it should be recognised that data from non-randomised studies are available, for example on the use of chemotherapy only in very young children with promising results for children without metastatic disease. We found only one RCT addressing standard-dose RT without chemotherapy versus reduced-dose RT with chemotherapy, so no definitive conclusions can be made. More high-quality research is needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-11-17 12:04:46 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-11-13 16:28:37 +0100" MODIFIED_BY="[Empty name]">
<P>Medulloblastoma represents one of the most common malignant brain tumours in childhood, occurring mostly in children younger than 10 years of age. Survival of children with medulloblastoma is correlated with the age at diagnosis, the presence of metastatic disease, the treatment given and the presence of extensive residual disease following neurosurgery. Five-year event-free survival (EFS) varies from around 30% to more than 80% (<LINK REF="REF-Kortmann-2000" TYPE="REFERENCE">Kortmann 2000</LINK>; <LINK REF="REF-Zeltzer-1999" TYPE="REFERENCE">Zeltzer 1999</LINK>). More recently, the histological subtypes and molecular characteristics of the tumour were added as prognostic markers. While nodular/desmoplastic tumours appear to have a favourable prognosis (<LINK REF="REF-Rutkowski-2010" TYPE="REFERENCE">Rutkowski 2010</LINK>), children with large cell/anaplastic medulloblastoma have a poor prognosis (<LINK REF="REF-Brown-2000" TYPE="REFERENCE">Brown 2000</LINK>; <LINK REF="REF-Ellison-2005" TYPE="REFERENCE">Ellison 2005</LINK>; <LINK REF="REF-Gajjar-2006" TYPE="REFERENCE">Gajjar 2006</LINK>; <LINK REF="REF-Giangaspero-1999" TYPE="REFERENCE">Giangaspero 1999</LINK>; <LINK REF="REF-Grotzer-2001" TYPE="REFERENCE">Grotzer 2001</LINK>; <LINK REF="REF-Northcott-2011" TYPE="REFERENCE">Northcott 2011</LINK>). Molecular characteristics with a favourable prognosis are nuclear expression of beta-catenin (<LINK REF="REF-Ellison-2005" TYPE="REFERENCE">Ellison 2005</LINK>; <LINK REF="REF-Gajjar-2006" TYPE="REFERENCE">Gajjar 2006</LINK>), and TrkC expression (<LINK REF="REF-Grotzer-2000" TYPE="REFERENCE">Grotzer 2000</LINK>; <LINK REF="REF-Rutkowski-2007" TYPE="REFERENCE">Rutkowski 2007</LINK>); a worse prognosis is related to MYC/MYCN amplification (<LINK REF="REF-Pfister-2009" TYPE="REFERENCE">Pfister 2009</LINK>). Four main subgroups of medulloblastoma exist; Wnt (very good prognosis), Shh (intermediate prognosis), Group 3 (poor prognosis) and Group 4 (intermediate prognosis) (<LINK REF="REF-Taylor-2012" TYPE="REFERENCE">Taylor 2012</LINK>).</P>
<P>For decades, the standard therapy for children with medulloblastoma has been neurosurgery with a maximum of debulking, followed by craniospinal radiotherapy (CSRT). However, craniospinal irradiation causes significant long-term adverse effects. Children aged less than 36 months who received whole-brain radiotherapy (cranial radiotherapy (CRT)) as part of their treatment of a cerebellar tumour showed more neurocognitive and psychosocial deficits than non-irradiated infants (<LINK REF="REF-Copeland-1999" TYPE="REFERENCE">Copeland 1999</LINK>). Palmer et al. found that the decline in intelligence quotient (IQ) values was the result of an inability to acquire new skills and information at a rate comparable to their healthy peers, and not to a loss of previously acquired information and skills (<LINK REF="REF-Palmer-2001" TYPE="REFERENCE">Palmer 2001</LINK>). On the endocrinological level, deficiencies following CSRT have been known for a very long time (<LINK REF="REF-Livesey-1990" TYPE="REFERENCE">Livesey 1990</LINK>; <LINK REF="REF-Shalet-1977" TYPE="REFERENCE">Shalet 1977</LINK>). In accordance, Spoudeas et al. showed that growth hormone is especially sensitive to radiation injury (<LINK REF="REF-Spoudeas-2003" TYPE="REFERENCE">Spoudeas 2003</LINK>), and Gurney et al. demonstrated hypothyroidism in 30% of irradiated participants and a growth hormone deficiency in 39.2% of irradiated participants (<LINK REF="REF-Gurney-2003" TYPE="REFERENCE">Gurney 2003</LINK>).</P>
<P>As a consequence, chemotherapy has been introduced in older children to improve survival and diminish the long-term effects caused by radiotherapy (RT), while in very young children, its goal is mainly to omit or delay RT, while preserving or even improving survival rates (<LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>; <LINK REF="REF-Geyer-2005" TYPE="REFERENCE">Geyer 2005</LINK>; <LINK REF="REF-Grill-2005" TYPE="REFERENCE">Grill 2005</LINK>; <LINK REF="REF-Merchant-2008" TYPE="REFERENCE">Merchant 2008</LINK>; <LINK REF="REF-Oyharcabal_x002d_Bourden-2005" TYPE="REFERENCE">Oyharcabal-Bourden 2005</LINK>; <LINK REF="REF-Packer-2006" TYPE="REFERENCE">Packer 2006</LINK>; <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>; <LINK REF="REF-Rutkowski-2005" TYPE="REFERENCE">Rutkowski 2005</LINK>). In recent years, high-dose chemotherapy followed by stem cell rescue has been increasingly used for children with a poor prognosis (<LINK REF="REF-Gajjar-2006" TYPE="REFERENCE">Gajjar 2006</LINK>; <LINK REF="REF-Gandola-2009" TYPE="REFERENCE">Gandola 2009</LINK>; <LINK REF="REF-Grill-2005" TYPE="REFERENCE">Grill 2005</LINK>; <LINK REF="REF-P_x00e9_rez_x002d_Martinez-2004" TYPE="REFERENCE">Pérez-Martinez 2004</LINK>).</P>
<P>Several randomised controlled trials (RCT) have been conducted to analyse the effects of chemotherapy, and to detect possible subgroups of children that might benefit most from chemotherapy. However, until now, no systematic review had been carried out.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-11-13 16:33:00 +0100" MODIFIED_BY="[Empty name]">
<P>Primary objectives: 1. to determine the EFS/disease-free survival (EFS/DFS) and overall survival (OS) in children with medulloblastoma receiving chemotherapy as a part of their primary treatment, as compared with children not receiving chemotherapy as part of their primary treatment; 2. to determine EFS/DFS and OS in children with medulloblastoma receiving standard-dose RT without chemotherapy, as compared with children receiving reduced-dose RT with chemotherapy as their primary treatment.</P>
<P>Secondary objectives: to determine possible adverse effects of chemotherapy and RT, including long-term adverse effects and effects on quality of life.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-11-15 15:32:24 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-11-13 16:41:54 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-11-13 16:39:01 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary objective 1</HEADING>
<P>RCTs comparing the EFS/DFS or OS (or both) in children with medulloblastoma receiving chemotherapy as part of their primary treatment compared with children not receiving chemotherapy as part of their primary treatment.</P>
<P>As mentioned in the protocol of this review, we would only have included controlled clinical trials (CCTs) if we had identified no RCTs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary objective 2</HEADING>
<P>RCTs comparing the EFS/DFS or OS (or both) in children with medulloblastoma receiving standard-dose RT without chemotherapy compared with children receiving reduced-dose RT with chemotherapy as their primary treatment.</P>
<P>As mentioned in the protocol of this review, we would only have included CCTs if we had identified no RCTs.</P>
</SUBSECTION>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-10-07 14:16:45 +0200" MODIFIED_BY="[Empty name]">
<P>Children (aged 0 to 21 years) with a primary diagnosis of medulloblastoma.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-11-13 16:40:51 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary objective 1</HEADING>
<P>Neurosurgery or RT (or both) with or without chemotherapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary objective 2</HEADING>
<P>Neurosurgery and standard-dose RT (30 Gray (Gy) or greater on the craniospinal axis (CSA) and 50 Gy or greater on the posterior fossa) without chemotherapy or reduced-dose RT (less than 30 Gy on the CSA and 50 Gy or greater on the posterior fossa) with chemotherapy.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-11-13 16:41:54 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<OL>
<LI>EFS/DFS, defined as the time to recurrence or progression of primary disease or death from any cause.</LI>
<LI>OS, defined as the time to death from any cause.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<OL>
<LI>Adverse effects, defined as toxicities grade 3 or higher (as classified by, for example, the Common Toxicity Criteria of the World Health Organization (WHO)) and including long-term adverse effects, such as neurocognitive impairment and endocrinological deficiencies (as defined by the authors of the original study).</LI>
<LI>Quality of life.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-11-13 16:43:25 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following electronic databases:</P>
<OL>
<LI>the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 7);</LI>
<LI>MEDLINE/PubMed (from 1966 to 6 August 2013);</LI>
<LI>EMBASE/Ovid (from 1980 to 6 August 2013).</LI>
</OL>
<P>The search strategies for the different electronic databases are shown in <A HREF="http://www.archie.cochrane.org/sections/documents/view?document=A9AEFB8682E26AA200D4F13AB0F965A1&amp;format=REVMAN#APP-01">Appendix 1</A>; <A HREF="http://www.archie.cochrane.org/sections/documents/view?document=A9AEFB8682E26AA200D4F13AB0F965A1&amp;format=REVMAN#APP-02">Appendix 2</A>; and <A HREF="http://www.archie.cochrane.org/sections/documents/view?document=A9AEFB8682E26AA200D4F13AB0F965A1&amp;format=REVMAN#APP-03">Appendix 3</A>.<BR/>
</P>
<P>We handsearched the reference lists of relevant articles and review articles for information about trials, published or unpublished, not registered in CENTRAL, MEDLINE or EMBASE. We also scanned the conference proceedings of the International Society for Paediatric Oncology (SIOP), American Society for Pediatric Hematology and Oncology (ASPHO) and the International Symposium of Paediatric Neuro-Oncology (ISPNO) from 2001 to 2008, if available electronically and otherwise by handsearching. We searched for ongoing trials by scanning the International Standard Randomised Controlled Trial Number (ISRCTN) register and the National Institutes of Health Register (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>; both screened 15 August 2013). We applied no language restrictions.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-11-15 15:32:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Study identification</HEADING>
<P>Two review authors independently identified studies meeting the inclusion criteria on grounds of the title or abstract (or both) and if necessary obtained the full-text reports for closer inspection. We reported details of reasons for exclusion of any study considered for the review clearly in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. We resolved discrepancies by consensus and required no third-party arbitration. We reported full details of included studies in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies</HEADING>
<P>Two review authors independently assessed risk of bias in included studies according to the following criteria: concealment of treatment allocation; blinding of care provider, blinding of participants, blinding of outcome assessor (for each outcome separately); intention-to-treat (ITT) analyses (for each outcome separately) and completeness of follow-up (for each outcome separately). We have used the definitions as described in the module of the Cochrane Childhood Cancer Group at the time of writing the protocol for this systematic review (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). We resolved discrepancies between review authors by consensus and required no third-party arbitration.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Two review authors independently performed data extraction using standardised forms. We extracted data on:</P>
<OL>
<LI>characteristics of participants (e.g. age, sex, tumour staging, histological subtype and molecular markers);</LI>
<LI>characteristics of interventions (e.g. extent of surgical resection, posterior fossa and CSRT dose, type and dosage of chemotherapy, duration of chemotherapy, route of delivery of chemotherapy);</LI>
<LI>characteristics of outcome measures (see <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>);</LI>
<LI>duration of follow-up.</LI>
</OL>
<P>In cases of disagreement between review authors, we re-examined the abstracts and articles and discussed findings until we achieved consensus. We required no third-party arbitration.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>We entered data into Review Manager 5 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>), and analysed data according to the guidelines of the Cochrane <I>Handbook for Systematic Reviews of Interventions </I>(<A HREF="http://www.archie.cochrane.org/sections/documents/view?document=A9AEFB8682E26AA200D4F13AB0F965A1&amp;format=REVMAN#REF-Higgins-2008">Higgins 2008</A>). For dichotomous variables, we calculated risk ratio (RR) and 95% confidence intervals (CI). For the assessment of survival, we used the generic inverse variance function of Review Manager 5 to combine logs of the hazard ratios (HRs) (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>) and reported 95% CI. We used Parmar's method if HRs had not been explicitly presented in the study (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>). We extracted data by allocation intervention, irrespective of compliance with the allocated intervention, in order to allow an ITT analysis. If it was not possible to perform an ITT analysis, we stated this. We assessed heterogeneity both by visual inspection of the forest plots and by a formal statistical test for heterogeneity (i.e. the I<SUP>2</SUP> statistic). If there was evidence of substantial heterogeneity (I<SUP>2</SUP> greater than 50%) (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>), we reported this. We used a random-effects model for the estimation of treatment effects throughout the review. . We pooled data if we identified two or more studies, otherwise we summarised the results descriptively. For outcomes where only one study was available, we were unable to calculate an RR if one of the treatment arms experienced no events and we used the Fischer's exact test instead (calculated using GraphPad software; <A HREF="http://www.graphpad.com/quickcalcs/contingency1.cfm">www.graphpad.com/quickcalcs/contingency1.cfm</A>). Where possible, we separated data for younger/older children and high-risk/non-high-risk children (i.e. subgroups). For all outcomes for which pooling was possible, we performed sensitivity analyses for all quality criteria separately. We excluded the low-quality studies and the studies for which the quality was unclear and compared the results of the good-quality studies with the results of all available studies. We considered the quality of studies included in the analyses in the interpretation of the results of the review. We planned to construct a funnel plot to ascertain graphically the existence of publication bias. However, generally, tests for funnel plot asymmetry should be used only when there are at least 10 studies included in the meta-analysis, because when there are fewer studies the power of the tests is too low to distinguish chance from real asymmetry (<A HREF="http://www.archie.cochrane.org/sections/documents/view?document=A9AEFB8682E26AA200D4F13AB0F965A1&amp;format=REVMAN#REF-Higgins-2008">Higgins 2008</A>). Since only a maximum of four trials could be included in the different meta-analyses, we did not construct funnel plots.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-11-17 12:04:46 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-11-17 12:04:46 +0100" MODIFIED_BY="[Empty name]">
<P>After performing the searches of the electronic databases of CENTRAL (277 studies; some studies were included twice due to updates of the search), MEDLINE (1936 studies; some studies were included twice due to updates of the search) and EMBASE (1258 studies; some studies were included twice due to updates of the search) we excluded 3459 articles based on the title or abstract (or both) since they were not RCTs, did not compare children treated with chemotherapy with children treated without chemotherapy, did not include children at all or did not include children with medulloblastoma. We excluded a further four articles after assessing the full-text article for reasons described in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. Therefore, we included eight articles that fulfilled all the criteria for considering studies for this review. Two of these eight articles described the same study (<LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>); in one article, children eligible for both our objectives were included (<LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK>; <LINK REF="STD-Bailey-1995-RTvslowRT_x002f_CT" TYPE="STUDY">Bailey 1995 RTvslowRT/CT</LINK>).</P>
<P>We found no further studies by scanning the reference lists of relevant studies and reviews and the conference proceedings of SIOP, ASPHO and ISPNO. In addition, we identified no ongoing studies by scanning the ongoing trials databases.</P>
<P>Therefore, the total number of identified RCTs was eight. Seven studies compared children with medulloblastoma receiving chemotherapy as a part of their treatment with children not receiving chemotherapy as part of their treatment. One study compared children with medulloblastoma receiving standard-dose RT without chemotherapy with children receiving reduced-dose RT with chemotherapy. <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> shows the PRISMA flow diagram.</P>
<P>Characteristics of included studies are summarised below (for further details see the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table).</P>
<SUBSECTION>
<HEADING LEVEL="3">Description of studies comparing treatment including and treatment not including chemotherapy</HEADING>
<P>In the seven RCTs that compared treatment including versus treatment not including chemotherapy the total number of included children was 1080; 499 children in the experimental arm (receiving chemotherapy) and 502 children in the standard arm; for 79 children (from <LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK>), it was unclear to which treatment arm they were randomised. Ages of the children were not mentioned in two studies, and ranged from zero to 20 years in the other RCTs. Chemotherapy was administered during and after RT in three studies, before RT in two studies (thus delaying the start of RT) and after RT in two studies. Chemotherapy regimens contained vincristine in all seven RCTs, but in combination with many different other chemotherapeutics: etoposide in two studies; procarbazine in two studies; predniso(lo)ne in three studies; CCNU in two studies and cisplatin, methotrexate, nitrogen mustard, carboplatin, cyclophosphamide and intrathecal methotrexate and hydrocortisone respectively in one study. CRT doses varied from 25 to 45 Gy; some studies reduced this dose in children younger than either two or three years of age (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for more information on RT doses in individual studies). Prescribed dose to the fossa posterior was 50 Gy or greater in all studies; however, some studies reduced this dose in children younger than either two or three years. Only two studies mentioned the actual received RT doses. <I>
<BR/>
</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Description of studies comparing treatment with standard-dose radiotherapy and treatment with reduced-dose radiotherapy and chemotherapy</HEADING>
<P>Only one study compared children receiving standard-dose RT without chemotherapy with children receiving reduced-dose RT with chemotherapy (<LINK REF="STD-Bailey-1995-RTvslowRT_x002f_CT" TYPE="STUDY">Bailey 1995 RTvslowRT/CT</LINK>). In children receiving chemotherapy, the start of RT was delayed as compared with children only receiving RT. In this study, 76 children were eligible for evaluation (40 in the standard-dose RT arm and 36 in the reduced-dose RT arm). The exact ages of the children were unclear, but to be eligible for inclusion they had to be aged between zero and 16 years of age. According to protocol of the study, in the reduced-dose arm, the RT dose to the CSA was reduced to 25 Gy instead of 35 Gy, while the tumour-bearing area received 55 Gy in both arms. In children under two years of age, reduced RT doses were recommended (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for more information). In the combined treatment arm, chemotherapy was administered before RT. The chemotherapy regimen consisted of vincristine, procarbazine, methotrexate and prednisolone.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-11-15 15:51:33 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for the exact scores per included study.</P>
<SUBSECTION>
<HEADING LEVEL="3">Risk of bias in studies comparing treatment including and treatment not including chemotherapy</HEADING>
<P>The search identified seven studies.</P>
<P>Two studies applied a concealed treatment allocation (<LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK>; <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>), whereas in five studies this was unclear (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>; <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>; <LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>; <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>; <LINK REF="STD-Van-Eys-1981" TYPE="STUDY">Van Eys 1981</LINK>).</P>
<P>None of the seven studies blinded care providers and participants to treatment. However, it should be noted that due to the nature of the interventions blinding of care providers and participants was impossible.</P>
<P>For blinding of the outcome assessors, we scored each outcome separately, with the exception of OS, since for that outcome blinding was not relevant. Six studies evaluated EFS/DFS (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>; <LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK>; <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>; <LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>; <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>; <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>): in all studies, it was unclear if the outcome assessor was blinded to treatment. Five studies evaluated adverse effects: in all studies, it was unclear if the outcome assessor was blinded to treatment (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>; <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>; <LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>; <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>; <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>).</P>
<P>We scored the presence of an ITT analysis for each outcome separately. Six studies reported EFS/DFS. Two of the six studies used an ITT analysis (<LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK>; <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>), whereas this was unclear in four studies (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>; <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>; <LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>; <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>). Four studies reported OS. It was unclear if an ITT analysis was used in all four studies (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>; <LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>; <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>; <LINK REF="STD-Van-Eys-1981" TYPE="STUDY">Van Eys 1981</LINK>). Five studies reported adverse effects. One of the five studies used an ITT analysis (<LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>), whereas this was unclear in four studies (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>; <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>; <LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>; <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>).</P>
<P>We scored participants lost to follow-up for each outcome separately. Six studies evaluated EFS/DFS. Some participants were lost to follow-up in one of the six studies (<LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>), whereas in five studies this was unclear (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>; <LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK>; <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>; <LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>; <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>). For OS, the number of participants lost to follow-up was unclear in all four studies (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>; <LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>; <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>; <LINK REF="STD-Van-Eys-1981" TYPE="STUDY">Van Eys 1981</LINK>). Five studies reported adverse effects. Some participants were lost to follow-up in one study (<LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>), whereas in four studies this was unclear (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>; <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>; <LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>; <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>).</P>
<P>In conclusion, selection bias (based on concealment of treatment allocation) could not be ruled out in five of the seven included studies. Performance bias (based on blinding of the care provider and participant) could not be ruled out in any of the included studies. Detection bias (based on blinding of the outcome assessor) could not be ruled in any of the studies evaluating EFS/DFS and adverse effects. Attrition bias (based on the use of an ITT analysis and completeness of follow-up) could not be ruled out in any of the studies evaluating EFS/DFS, OS and adverse effects.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Risk of bias in studies comparing treatment with standard-dose radiotherapy and treatment with reduced-dose radiotherapy and chemotherapy</HEADING>
<P>The search identified one study.</P>
<P>This study applied a concealed treatment allocation. The care provider and participants were not blinded to treatment, but it should be noted that due to the nature of the interventions, blinding of care providers and participants was impossible. For EFS/DFS, it was unclear whether the outcome assessor was blinded to treatment. For EFS/DFS, this study used an ITT analysis. For EFS/DFS, the number of participants lost to follow-up was unclear.</P>
<P>In conclusion, in this study, selection bias (based on concealment of treatment allocation) could be ruled out, whereas performance bias (based on blinding of the care provider and participant), detection bias (based on blinding of the outcome assessor) and attrition bias (based on the use of an ITT analysis and completeness of follow-up) could not be ruled out.<BR/>
</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-11-17 12:04:15 +0100" MODIFIED_BY="[Empty name]">
<P>Not all articles allowed data extraction for all outcomes; see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for a more detailed description of the extractable outcomes of each study.</P>
<P>In the <LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK>/<LINK REF="STD-Bailey-1995-RTvslowRT_x002f_CT" TYPE="STUDY">Bailey 1995 RTvslowRT/CT</LINK> study, children were randomised to one of four treatment arms: 1. standard-dose RT only, 2. reduced-dose RT only, 3. chemotherapy plus standard-dose RT or 4. chemotherapy plus reduced-dose RT. In children receiving chemotherapy, the start of RT was delayed. For the analyses of treatment including and treatment not including chemotherapy, children receiving RT only (either standard or reduced dose) (treatment arms 1 and 2) were compared with children receiving both chemotherapy and RT (either the standard or reduced dose) (treatment arms 3 and 4). For the analyses of treatment with standard-dose RT and treatment with reduced-dose RT and chemotherapy, children from treatment arm 1 were compared with children from treatment arm 4. Children from only treatment arm 2 (reduced-dose RT only) were not included in the analyses, since comparing reduced-dose RT without the addition of chemotherapy was not an objective of our review.</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies comparing treatment including and treatment not including chemotherapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Event-free survival or disease-free survival</HEADING>
<P>We were able to extract data on EFS/DFS from six trials (see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>The trials of <LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK> and <LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>, including 300 children, used comparable outcome definitions (i.e. time to recurrence or progression of primary disease or death from any cause; for further details see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table) and, therefore, we could pool their results. The meta-analysis showed no significant difference between treatment including and treatment not including chemotherapy (HR 1.02; 95% CI 0.70 to 1.47; P value = 0.93). There was no heterogeneity (I<SUP>2</SUP> = 0%).</P>
<P>The trials of <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK> and <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>, including 465 children, used comparable outcome definitions (i.e. time to recurrence or death from any cause; for further details see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table) and, therefore, we pooled their results. The meta-analysis showed a significant difference in favour of children treated with chemotherapy (HR 0.70; 95% CI 0.54 to 0.91; P value = 0.007). There was no heterogeneity (I<SUP>2</SUP> = 0%).</P>
<P>In the study of <LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>, including 48 children, no definition for DFS was provided and the definition of EFS used by <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>, including 233 children, was not comparable to the other definitions, therefore, we could not pool the results. However, in both studies there was no significant difference between treatment including and treatment not including chemotherapy (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>: HR 1.67; 95% CI 0.59 to 4.71; P value = 0.34; <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>: HR 0.84; 95% CI 0.58 to 1.21; P value = 0.34). For <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>, an ITT analysis was not possible, since 42 children were not randomised (21 in each treatment arm) and 12 children switched between treatment arms after randomisation (six in each treatment arm).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Overall survival</HEADING>
<P>We were able to extract data on OS from four trials including 332 children (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>; <LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>; <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>; <LINK REF="STD-Van-Eys-1981" TYPE="STUDY">Van Eys 1981</LINK>). The meta-analysis showed no significant difference between treatment including and treatment not including chemotherapy (HR 1.06; 95% CI 0.67 to 1.67; P value = 0.80; see <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). There was no substantial heterogeneity detected (I<SUP>2</SUP> = 13%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects grade 3 or higher</HEADING>
<P>Six studies evaluated eight different adverse effects grade 3 or higher (see <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). Of these, only two were long-term adverse effects (reduction in IQ and secondary malignant disease). The others were all short-term adverse effects. Treatment-related mortality was reported in three studies but the other adverse effects were evaluated in only one study. Therefore, we could only perform a meta-analysis for treatment-related mortality.</P>
<SUBSECTION>
<HEADING LEVEL="5">Alopecia grade 3</HEADING>
<P>We were able to extract data on acute alopecia grade 3 from one trial including 48 children (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>). There was no significant difference between treatment arms as all children had alopecia grade 3 (RR 1.00; 95% CI 0.92 to 1.08; P value = 1.00). Hair re-growth occurred in all children six weeks after ending RT and chemotherapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Reduction in intelligence quotient</HEADING>
<P>We were able to extract data on reduction in IQ from one trial including 48 children (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>). There were 13 cases (reduction of 12% to 21% in comparison with normal siblings) among 27 children randomised to treatment including chemotherapy and 13 cases (reduction of 8% to 20% in comparison with normal siblings) among 21 children randomised to treatment not including chemotherapy. There was no significant difference between treatment arms (RR 0.78; 95% CI 0.46 to 1.30; P value = 0.34).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary malignant disease</HEADING>
<P>We were able to extract data on secondary malignant disease from one trial including 286 children (<LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>). The length of follow-up was not mentioned; the maximal follow-up was 13 years. There were no cases among 141 children randomised to treatment including chemotherapy and two cases among 145 children randomised to treatment not including chemotherapy. One child developed a meningioma within the area of the posterior fossa boost nine years after treatment; one child developed a low-grade sarcoma in the occipital region 10 years after treatment. Since one treatment arm experienced no events, we were unable to calculate an RR, but there was no significant difference between treatment arms using the Fisher's exact test (P value = 0.50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Severe infections</HEADING>
<P>We were able to extract data on severe infections from one trial including 233 children (<LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>). There were 11 cases among 115 children randomised to treatment including chemotherapy and two cases among 118 children randomised to treatment not including chemotherapy. There was a significant difference in the occurrence of severe infections in favour of children randomised to treatment not including chemotherapy (RR 5.64; 95% CI 1.28 to 24.91; P value = 0.02). An ITT analysis was not possible, since 42 children were not randomised (21 in each treatment arm) and 12 children switched between treatment arms after randomisation (six in each arm).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Haematological toxicity grade 3 or 4</HEADING>
<P>We were able to extract data on haematological toxicity grade 3 or 4 (white blood cells or platelet count, or both) from one trial including 71 patients (<LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>). There were five cases (all grade 4) among 36 children randomised to treatment including chemotherapy and nine cases (eight cases were grade 3; one case was grade 4) among 35 children randomised to treatment not including chemotherapy. In children who received chemotherapy, it was started 4 weeks after the completion of RT. There was no significant difference between treatment groups (RR 0.54; 95% CI 0.20 to 1.45; P value = 0.22).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hepatotoxicity grade 3</HEADING>
<P>We were able to extract data on hepatotoxicity grade 3 from one trial including 71 patients (<LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>). There was one case among 36 children randomised to treatment including chemotherapy and no cases among 35 children randomised to treatment not including chemotherapy. Since one treatment arm experienced no events, we were unable to calculate an RR, but there was no significant difference between treatment groups using the Fisher's exact test (P value = 1.00).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fever and neutropenia</HEADING>
<P>We were able to extract data on fever and neutropenia from one trial including 71 patients (<LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>). There were seven cases among 36 children randomised to treatment including chemotherapy and no cases among 35 children randomised to treatment not including chemotherapy. Since one treatment arm experienced no events, we were unable to calculate an RR, but there was a significant difference in favour of treatment not including chemotherapy using the Fisher's exact test (P value = 0.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment-related mortality</HEADING>
<P>We were able to extract data on treatment-related mortality from three trials including 284 children (<LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>; <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>; <LINK REF="STD-Van-Eys-1981" TYPE="STUDY">Van Eys 1981</LINK>). There were four cases among 142 children randomised to treatment including chemotherapy and one case among 142 children randomised to treatment not including chemotherapy. Children in the chemotherapy arm died from pneumococcal sepsis and pericarditis (one child), septicaemia and toxic dilation of the gastrointestinal tract (one child), sepsis (one child) and life-threatening myelosuppression (one child, but the exact cause of death was not ascertained). One child in the treatment not including chemotherapy arm died from disseminated intravascular coagulopathy and meningitis. The meta-analysis showed no significant difference between treatment groups (RR 2.37; 95% CI 0.43 to 12.98; P value = 0.32). There was no heterogeneity (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life</HEADING>
<P>None of the studies evaluated quality of life.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>The results of the sensitivity analyses were consistent among the trials and did not differ from the overall analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>Three studies presented adequate survival data on younger/older children (<LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>), or high-risk/non-high-risk children (<LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>; <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>). Since definitions used for high-risk/non-high-risk children were not comparable between the studies, we could not pool results. Thus, we have summarised the results descriptively (i.e. as presented in the individual articles).</P>
<SUBSECTION>
<HEADING LEVEL="4">Younger versus older children</HEADING>
<P>One study reported EFS/DFS and OS for three age groups: aged three to seven, eight to 11 and 12 to 16 years. There was no significant effect of age on outcome in relation to EFS/DFS (P value = 0.44) or OS (P value = 0.54) (<LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">High-risk versus non-high-risk children</HEADING>
<P>In one study, for the 113 children with early-stage disease (T1 and T2), chemotherapy had no effect on EFS/DFS (<LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>). However, with advanced disease (T3 and T4), the 91 children who received chemotherapy had significantly better EFS/DFS than the 72 children who did not receive chemotherapy (P value = 0.002).</P>
<P>In one study, there was no benefit in EFS/DFS from chemotherapy in 67 children who had tumour stage T1-2/M0 and in 124 children with tumour stage T3-4/M0 (P value = 0.27; <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>). There were too few children with low T-stage and advanced M-stage disease (T3 or 4, M1 to 3; 12 children) for analysis, but the group with advanced T-stage and M-stage disease (T3 or T4, M1 to M3) showed a striking effect of chemotherapy (46% with chemotherapy versus 0% with no chemotherapy; P value = 0.006). It should be noted that these data were not from an ITT analysis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Studies comparing treatment with standard-dose radiotherapy and treatment with reduced-dose radiotherapy and chemotherapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Event-free survival or disease-free survival</HEADING>
<P>One study, including 76 children, reported data on EFS/DFS (<LINK REF="STD-Bailey-1995-RTvslowRT_x002f_CT" TYPE="STUDY">Bailey 1995 RTvslowRT/CT</LINK>). There was no significant difference between treatment with standard-dose RT and treatment with reduced-dose RT and chemotherapy (HR 1.54; 95% CI 0.81 to 2.94; P value = 0.19) (see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other outcomes</HEADING>
<P>We found no studies comparing the effects of treatment with standard-dose RT and treatment with reduced-dose RT and chemotherapy on OS, adverse effects or quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<P>We found no data on younger/older children and high-risk/non-high-risk children; thus, we could not perform subgroup analyses.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-11-17 11:08:23 +0100" MODIFIED_BY="[Empty name]">
<P>This systematic review evaluated the current state of evidence on the effectiveness of treatment including chemotherapy compared with treatment not including chemotherapy in children with medulloblastoma. Furthermore, we evaluated the current state of evidence on the effectiveness of treatment with standard-dose RT compared with treatment with reduced-dose RT and chemotherapy in children with medulloblastoma. We only included RCTs since it is widely recognised that an RCT is the only study design that can produce unbiased evidence on the use of different treatment options, provided that the design and execution are adequate.</P>
<SUBSECTION>
<HEADING LEVEL="2">Treatment including chemotherapy compared with treatment not including chemotherapy</HEADING>
<P>We identified seven RCTs, published between 1981 and 2005 (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>; <LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK>; <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>; <LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>; <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>; <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>; <LINK REF="STD-Van-Eys-1981" TYPE="STUDY">Van Eys 1981</LINK>). Unfortunately, different definitions of study end points, numerous chemotherapy regimens and doses (none of which would be considered standard of care today), changes inherent to three decades of technological and histo/biological knowledge and the fact that, in most studies, results for different risk groups were not reported separately were major obstacles in comparing the results of the different studies.</P>
<P>The studies used three different definitions of EFS and DFS, and one study provided no definition of DFS. This made pooling of the results of all studies impossible. The definitions of other outcome measures (OS and adverse events) were comparable between studies. Furthermore, none of the studies used exactly the same chemotherapy schedule. Eleven different drugs were administered in seven different regimens and the actual received doses of chemotherapy were not mentioned in most of the studies. For evaluation of the effect of chemotherapy, this is important information. The lack of efficacy of a certain chemotherapy regimen might be due to dose reduction due to toxicity. In that respect, it is important to realise that the inclusion period encompassed 30 years. In this time, supportive care has improved substantially and the expectation might thus be that in later time periods, stricter adherence to the chemotherapy protocols was possible. Furthermore, over three decades, both diagnosis and treatment have evolved substantially: improved imaging techniques (not all included studies used magnetic resonance imaging as imaging modality) and different staging criteria. In addition, neurosurgical and RT procedures have changed substantially.</P>
<P>Only one study provided information on histological subtypes of medulloblastoma, that is, nodular/desmoplastic versus classical variants, and no study mentioned large cell/anaplastic variants. Evaluating the effect of chemotherapy by considering all these subtypes as one group may result in under- or overestimating the effectiveness of chemotherapy. No study provided information on molecular characteristics of the medulloblastomas. New molecular subgroups have emerged that show clear differences in prognosis of children with medulloblastoma (<LINK REF="REF-Taylor-2012" TYPE="REFERENCE">Taylor 2012</LINK>). The included studies did not examine these molecular characteristics. This is likely to have influenced the overall results of the included studies, as did the fact that, in most studies, different risk groups were not analysed separately.</P>
<P>With regard to EFS/DFS, pooling of the trials of <LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK> and <LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK> including 300 children showed no significant advantage of the addition of chemotherapy; in these studies, EFS/DFS were defined as time to recurrence or progression of primary disease or death from any cause. This result was confirmed in two individual studies that we could not pool (<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>; <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>). In contrast, the meta-analysis of the studies of <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK> and <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK> including 465 children showed a significant difference in favour of treatment with chemotherapy; in these studies, EFS/DFS were defined as time to recurrence of primary disease or death from any cause and not including disease progression as an event might not be optimal. It should be noted that in the study of <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>, the difference in DFS reached statistical significance while the study was running, but, due to late relapses in the chemotherapy arm, this significance was no longer evident with longer follow-up.</P>
<P>The discordance between the two meta-analyses is difficult to explain. Whether the results in favour of chemotherapy in the second meta-analysis can be explained by the fact that the studies of <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK> and <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK> did not include progression of disease in their definition of EFS/DFS cannot be ruled out. The Primitive Neuroectodermal Tumour Study (PNET)-3 study of <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK> advised that people progressing under chemotherapy would go for immediate RT, but no actual data were given on the exact number of participants that progressed. It would be interesting to take into account the number of participants that progressed, and determine whether addition of chemotherapy would still give a significant EFS/DFS advantage.</P>
<P>Regarding OS, we pooled the results of four studies including 332 children. There was no significant difference in OS between treatment with and without chemotherapy.</P>
<P>Adverse effects (grade 3 or higher) were scarcely reported. Most adverse events were only mentioned in one RCT, or data were only provided for the chemotherapy arm and not for the RT only arm. Thus, as the risk of underreporting was real, caution must be taken in interpreting these results. Of eight different adverse effects grade 3 or higher, two (severe infections and fever/neutropenia) showed a significant difference in favour of the treatment not including chemotherapy. For the six other adverse effects (i.e. acute alopecia, reduction in IQ, secondary malignant disease, haematological toxicity, hepatotoxicity (all evaluated in one study); and treatment-related mortality (based on a meta-analysis of three studies including 284 children)), there was no significant difference between the treatment arms. However, in a small subgroup (26%) of participants included in the PNET-3 study (i.e. the same protocol as in the <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK> study), which was included in this review, permanent cranial alopecia was more prevalent in children receiving chemotherapy and RT compared with people receiving only RT (<LINK REF="STD-Rogers-2011" TYPE="STUDY">Rogers 2011</LINK>). The number of cases of secondary malignant disease in the study of <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK> (two cases of secondary malignant disease on 286 children treated) seems low in comparison to the Children's Oncology Group (COG) study, which reported 14 cases of secondary malignant disease at eight years of follow-up on 379 children treated (<LINK REF="REF-Packer-2010" TYPE="REFERENCE">Packer 2010</LINK>). Even taking into account the lower survival in the study of <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>, and thus the lower number of children at risk for developing a secondary malignant disease, the discrepancy remains. In the study of <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>, 66% of children were lost to follow-up by nine years. This might explain these results.</P>
<P>The health status of a subgroup of children (i.e. part of the surviving UK participants) included in the study of <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>, together with some participants who did receive the same treatment in a non-randomised manner, was reported separately (<LINK REF="REF-Bull-2007" TYPE="REFERENCE">Bull 2007</LINK>). In these participants, the addition of chemotherapy to CSRT was associated with a significant decrease in health status (assessed at a mean of 7.2 years after diagnosis). Unfortunately, quality of life was not evaluated in any of the included articles in this review.</P>
<P>In the individual studies, different subgroups were evaluated. One study provided survival data on children in different age groups (three to seven, eight to 11 and 12 to 16 years of age); there was no significant effect of age in relation to EFS/DFS and OS (<LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>). However, no comparison was made for children younger or older than three years of age, which is a broadly used cut-off point in determining risk group in children. Two trials examined EFS/DFS for the subgroups high-risk versus non-high-risk, but, as the definition of the risk groups was different in the two studies, we could not pool the results (<LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>; <LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>). The individual study results showed no significant difference in EFS/DFS between the treatment arms in some subgroups, while in other subgroups (all children with advanced disease, but differently defined) children receiving chemotherapy responded significantly better. The criteria for defining standard-risk disease versus high-risk disease have changed since 1990, but re-assigning people of those studies into risk groups that are commonly used today was not possible because of lack of information. As a result, no definitive conclusions were made regarding the effect of chemotherapy in the different subgroups as they would be classified in contemporary protocols.</P>
<P>'No evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. A benefit of chemotherapy cannot be excluded. The reason that some studies did not identify a significant difference between study arms could, besides reasons mentioned earlier, also be due to the number of participants included in these studies being too small to detect a difference between the treatment arms (i.e. low power). Furthermore, the length of follow-up could have been too short to detect a significant difference between the treatment arms. For example, for secondary malignant disease, the maximal follow-up was 13 years, but it is possible that in participants with a shorter follow-up, a secondary malignant disease has not yet developed, but will develop when follow-up increases.</P>
<P>The risk of bias in the included studies was difficult to assess due to a lack of reporting. As a result, we could not rule out the presence of selection bias, performance bias, detection bias and attrition bias. However, at the moment this is the best available evidence of RCTs comparing the effectiveness of treatment including chemotherapy compared with treatment not including chemotherapy in children with medulloblastoma. With regard to performance bias, it should be noted that due to the nature of the interventions, blinding of care providers and participants was virtually impossible. In this review, we only performed ITT analyses, since they provide the most realistic and unbiased answer to the question of clinical effectiveness (<LINK REF="REF-Lachin-2000" TYPE="REFERENCE">Lachin 2000</LINK>; <LINK REF="REF-Lee-1991" TYPE="REFERENCE">Lee 1991</LINK>). However, for <LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>, an ITT analysis was not possible, and therefore, we performed an as-treated analysis.</P>
<P>The results of this systematic review must be viewed in the context of the complete therapy (e.g. the effect of surgery and CSRT, and the different chemotherapy protocols used (such as different agents or different doses, or both)). We have pooled the results of all eligible studies, but, as stated before, the above mentioned items differed between the studies. As a result, in this systematic review, we can only provide conclusions on the concept of treatment including chemotherapy versus treatment not including chemotherapy. We cannot make conclusions with regard to specific treatment options (such as type of surgery, RT fields and doses, different chemotherapeutic agents and doses).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Treatment with standard-dose radiotherapy compared with treatment with reduced-dose radiotherapy and chemotherapy</HEADING>
<P>We identified one RCT, published in 1995, including 76 children (<LINK REF="STD-Bailey-1995-RTvslowRT_x002f_CT" TYPE="STUDY">Bailey 1995 RTvslowRT/CT</LINK>). The treatment protocol used in the study would not be considered standard of care today. Only EFS/DFS was evaluated and there was no significant difference between treatment arms. Unfortunately, there was no information on effects on OS, adverse effects and quality of life or for different subgroup analyses.</P>
<P>It should be noted that results of only a small proportion of the eligible participants have been presented (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table), and, as a result, there was a high risk of attrition bias. The same obstacles in interpreting the results as in the previous studies were encountered: the actual received doses of chemotherapy were not mentioned and the study did not provide information on histological subtypes of medulloblastoma or on molecular characteristics.</P>
<P>In this study, we ruled out selection bias, whereas we could not rule out performance bias, detection bias and attrition bias. However, at the moment this is the best-available evidence of RCTs comparing the effectiveness of treatment with standard-dose RT with treatment with reduced-dose RT and chemotherapy in children with medulloblastoma. With regard to performance bias, it should be noted that due to the nature of the interventions, blinding of care providers and participants was virtually impossible.</P>
<P>In addition, even though RCTs are the highest level of evidence, it should be recognised that data from non-randomised studies are available, for example on the use of chemotherapy only in very young children. The results are promising for children without metastatic disease (<LINK REF="REF-Grill-2005" TYPE="REFERENCE">Grill 2005</LINK>; <LINK REF="REF-Rutkowski-2005" TYPE="REFERENCE">Rutkowski 2005</LINK>), which is important since without craniospinal irradiation fewer long-term adverse effects will occur. Furthermore, it should be noted that in this systematic review, we did not evaluate the effect of reductions in radiation fields (at the tumour bed) and RT dose other than the definitions we used in this review for standard and reduced dose (as described in the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section). These issues are also important in further optimising the treatment of children with medulloblastoma and should be kept in mind.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-11-17 11:10:34 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-11-17 11:10:34 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Treatment including chemotherapy compared with treatment not including chemotherapy</HEADING>
<P>Only the meta-analysis of event-free survival/disease-free survival (EFS/DFS), not including disease progression during therapy in the definition, showed a significant difference in favour of treatment including chemotherapy. This finding was not confirmed in either the meta-analysis of EFS/DFS including disease progression during therapy in the definition or individual randomised controlled trials (RCTs) using unclear or other definitions of EFS/DFS (which showed no significant difference between treatment arms). The discordance between these results is difficult to explain. Not including disease progression as an event might not be optimal. We identified no significant difference in overall survival (OS) between treatment arms. Data on adverse effects were scarce. Out of eight reported adverse effects, of which seven were reported in one study only, severe infections and fever/neutropenia showed a significant difference in favour of treatment not including chemotherapy. For the other adverse effects, there was no significant difference between treatment arms. No information on quality of life was provided. In addition, we can make no definitive conclusions regarding the effect of treatment including and not including chemotherapy in different subgroups. However, two studies show that children with advanced disease might have an improved EFS/DFS when receiving chemotherapy, but we could not pool the results and also, some definitions of advanced disease as used in the included studies differed from the currently used definitions. The results of this systematic review must be viewed in the context of the complete therapy (e.g. the effect of surgery and craniospinal radiotherapy, and the different chemotherapy protocols used). Thus, this systematic review only allows a conclusion on the concept of treatment including chemotherapy versus treatment not including chemotherapy; we can make no conclusions regarding the best treatment strategy.</P>
<P>Several factors complicated the interpretation of results: different definitions of study end points, numerous chemotherapy regimens and doses, a long time span between the first and the last studies with important changes in supportive care and progress in imaging and treatment techniques in the meantime, no information on histological subtypes and molecular characteristics of the tumour, no uniform definition of standard-risk versus high-risk children and the fact that in most studies different risk groups were not analysed separately. In addition, the fact that we identified no significant differences between treatment arms could be, for example, the result of low power or too short a follow-up period. Based on the currently available evidence, we are unable to determine whether treatment with or without chemotherapy in children with medulloblastoma is preferable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Treatment with standard-dose radiotherapy compared with treatment with reduced-dose radiotherapy and chemotherapy</HEADING>
<P>Since we identified only one RCT comparing standard-dose radiotherapy with reduced-dose radiotherapy and chemotherapy, no definitive conclusions can be made about these treatments. In this small study group of 76 children, there was no significant difference in EFS/DFS, but this finding should be confirmed in other RCTs. The study did not report on OS, adverse effects and quality of life.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-11-15 15:45:04 +0100" MODIFIED_BY="[Empty name]">
<P>In order to state with a high level of certainty if and for which children the addition of chemotherapy (with or without reduced-dose radiotherapy) to the previous standard therapy of radiation only will improve treatment results in children with medulloblastoma, we need high-quality RCTs in which uniform stratification criteria for standard-risk and high-risk children are used, as well as uniform outcome definitions (including EFS/DFS, OS, adverse effects and quality of life). However, in the current treatment era, it is considered unethical to use RCTs of the former higher 'standard-dose' radiotherapy in one arm, as the long-term consequences are devastating. Thus, it is very unlikely that such high-quality RCTs will be developed in the future. It is widely recognised that an RCT is the only study design that can provide unbiased evidence on interventions, provided that the design and execution are adequate. Without evidence from high-quality RCTs, we have to acknowledge that the true efficacy of these treatments in children with medulloblastoma remains unclear.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-11-13 15:27:50 +0100" MODIFIED_BY="[Empty name]">
<P>The review authors wish to thank Leontien Kremer, the Co-ordinating Editor of the Childhood Cancer Group, for her support in preparing the protocol of the review. We would like to thank Edith Leclercq, the Trials Search Co-ordinator of the Childhood Cancer Group, for helping to develop the search strategy, for running the search strategy in the different databases and for providing us with the titles and abstracts of the searches. We thank Stichting Kinderen Kankervrij (KIKA), Netherlands for the financial support that made it possible to perform this systematic review. Dr. M. Massimino, Dr. R. Geyer and an undisclosed person kindly agreed to peer review our manuscript, for which we are grateful. The editorial base of the Cochrane Childhood Cancer Group is funded by KIKA. For survival analyses, the hazard ratio and associated statistics were calculated using an Excel spreadsheet developed by Matthew Sydes and Jayne Tierney of the MRC Clinical Trials Unit, London, UK.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-11-13 15:28:47 +0100" MODIFIED_BY="[Empty name]">
<P>Erna Michiels designed the study and wrote the protocol; identified the studies meeting the inclusion criteria; performed data extraction and risk of bias assessment of the included studies; searched for unpublished and ongoing studies; contributed to the interpretation of the results; wrote and revised the review.</P>
<P>Antoinette Schouten - van Meeteren critically reviewed the protocol; identified the studies meeting the inclusion criteria; performed data extraction and risk of bias assessment of the included studies; contributed to the interpretation of the results; critically reviewed the manuscript.</P>
<P>François Doz critically reviewed the protocol and the manuscript.</P>
<P>Geert Janssens critically reviewed the manuscript.</P>
<P>Elvira van Dalen designed the study and wrote the protocol; helped with developing the search strategy; identified studies meeting the inclusion criteria; searched for unpublished and ongoing studies; analysed the data; contributed to the interpretation of the results; wrote and revised the review.</P>
<P>All authors approved the final version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-11-17 11:42:01 +0100" MODIFIED_BY="[Empty name]">
<P>None.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-11-13 16:06:55 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-11-13 16:02:23 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-11-13 16:02:23 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abd-El_x002d_Aal-2005" MODIFIED="2014-11-13 15:58:12 +0100" MODIFIED_BY="[Empty name]" NAME="Abd El-Aal 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-11-13 15:58:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abd El-Aal HH, Mokhtar MM, Habib EE, El-Kashef AT, Fahmy ES</AU>
<TI>Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post-operative treatment of high-risk patients</TI>
<SO>Journal of the Egyptian National Cancer Institute</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>4</NO>
<PG>301-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailey-1995-CT-vs-no-CT" MODIFIED="2010-02-17 13:47:58 +0100" MODIFIED_BY="[Empty name]" NAME="Bailey 1995 CT vs no CT" YEAR="1995">
<REFERENCE MODIFIED="2009-06-18 16:05:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey CC, Gnekow A, Wellek S, Jones M, Round C, Brown J, et al</AU>
<TI>Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>3</NO>
<PG>166-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailey-1995-RTvslowRT_x002f_CT" MODIFIED="2010-02-17 13:49:23 +0100" MODIFIED_BY="[Empty name]" NAME="Bailey 1995 RTvslowRT/CT" YEAR="">
<REFERENCE MODIFIED="2010-02-17 13:49:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey CC, Gnekow A, Wellek S, Jones M, Round C, Brown J, et al</AU>
<TI>Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>3</NO>
<PG>166-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1990" MODIFIED="2010-03-01 14:24:18 +0100" MODIFIED_BY="[Empty name]" NAME="Evans 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-03-01 14:24:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans AE, Jenkin RDT, Sposto R, Ortega JA, Wilson CB, Wara W, et al</AU>
<TI>The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1990</YR>
<VL>72</VL>
<PG>572-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krischer-1991" MODIFIED="2010-03-01 14:24:52 +0100" MODIFIED_BY="[Empty name]" NAME="Krischer 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-03-01 14:24:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krischer JP, Ragab AH, Kun L, Kim TH, Laurent JP, Boyett JM, et al</AU>
<TI>Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1991</YR>
<VL>74</VL>
<PG>905-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tait-1990" MODIFIED="2014-11-13 15:59:06 +0100" MODIFIED_BY="[Empty name]" NAME="Tait 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-11-13 15:59:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris-Jones P</AU>
<TI>Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I)</TI>
<SO>European Journal of Cancer</SO>
<YR>1990</YR>
<VL>26</VL>
<NO>4</NO>
<PG>464-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-2003_x002f_4" MODIFIED="2010-03-01 14:26:14 +0100" MODIFIED_BY="[Empty name]" NAME="Taylor 2003/4" YEAR="">
<REFERENCE MODIFIED="2010-03-01 14:25:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, et al</AU>
<TI>Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>8</NO>
<PG>1581-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-01 14:26:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor RE, Bailey CC, Robinson KJ, Weston CL, Ellison D, Ironside J, et al</AU>
<TI>Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET-3 study of preradiotherapy chemotherapy for M0-M1 medulloblastoma</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>4</NO>
<PG>1184-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Eys-1981" MODIFIED="2014-11-13 16:02:23 +0100" MODIFIED_BY="[Empty name]" NAME="Van Eys 1981" YEAR="1981">
<REFERENCE MODIFIED="2014-11-13 16:02:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Eys J, Chen T, Moore T, Cheek W, Sexauer C, Starling K</AU>
<TI>Adjuvant chemotherapy for medulloblastoma and ependymoma using IV vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group study</TI>
<SO>Cancer Treatment Reports</SO>
<YR>1981</YR>
<VL>65</VL>
<PG>681-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-04-29 17:48:53 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Neidhardt-1982" MODIFIED="2010-12-08 12:42:27 +0100" MODIFIED_BY="[Empty name]" NAME="Neidhardt 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-12-08 12:42:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neidhardt M, Habermalz HJ, Henze G, Langermann HJ</AU>
<TI>Medulloblastoma study of the German Society for Pediatric Oncology, a first report</TI>
<TO>Medulloblastomstudie der Gesellschaft für pädiatrische onkologie, ein zwischenbericht</TO>
<SO>Klinische Padiatrie</SO>
<YR>1982</YR>
<VL>194</VL>
<PG>257-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-06-04 18:33:22 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neidhardt-1987a" MODIFIED="2010-12-08 12:42:08 +0100" MODIFIED_BY="[Empty name]" NAME="Neidhardt 1987a" YEAR="1987">
<REFERENCE MODIFIED="2010-12-08 12:42:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neidhardt M, Bailey CC, Gnekow A, Kleihues P, Michaelis J, Wellek S</AU>
<TI>Medulloblastoma therapy studies MBL 80 and MED 84 of the Society of Pediatric Oncology and the Société Internationale d'Oncologie Pédiatrique (SIOP)</TI>
<TO>Die medulloblastom-therapiestudien MBL 80 und MED 84 der Gesellschaft für Pädiatrische Onkologie (GPO) und der Société Internationale d'Oncologie Pédiatrique (SIOP)</TO>
<SO>Klinische Padiatrie</SO>
<YR>1987</YR>
<VL>199</VL>
<PG>188-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neidhardt-1987b" MODIFIED="2010-03-01 14:29:53 +0100" MODIFIED_BY="[Empty name]" NAME="Neidhardt 1987b" YEAR="1987">
<REFERENCE MODIFIED="2010-03-01 14:29:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neidhardt M, Bailey CC</AU>
<TI>Prospective randomized cooperative medulloblastoma trial (MED 84) of the International Society of Paediatric Oncology (SIOP) and of the (German) Society of Paediatric Oncology (GPO)</TI>
<SO>Childs Nervous System</SO>
<YR>1987</YR>
<VL>3</VL>
<PG>70-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rogers-2011" MODIFIED="2012-04-29 17:48:53 +0200" MODIFIED_BY="[Empty name]" NAME="Rogers 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-04-29 17:48:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rogers S, Donachie P, Sugden E, Sharpe G, English M, Robinson K, et al</AU>
<TI>Comparison of permanent hair loss in children with standard risk PNETS of the posterior fossa following radiotherapy alone or chemotherapy and radiotherapy after surgical resection</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2011</YR>
<VL>57</VL>
<NO>6</NO>
<PG>1074-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-11-13 16:06:55 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-11-13 16:06:55 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bloom-1981" MODIFIED="2010-03-03 13:03:34 +0100" MODIFIED_BY="[Empty name]" NAME="Bloom 1981" TYPE="CONFERENCE_PROC">
<AU>Bloom HJB</AU>
<TI>SIOP medulloblastoma and high grade ependymoma therapeutic clinical trial: preliminary results</TI>
<SO>Proceedings of the XIII meeting of the International Society of Paediatric Oncology (Marseilles)</SO>
<YR>1981</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2000" MODIFIED="2010-03-01 14:31:18 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brown HG, Kepner JL, Perlman EJ, Friedman HS, Strother DR, Duffner PK, et al</AU>
<TI>"Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study</TI>
<SO>Journal of Neuropathology and Experimental Neurology</SO>
<YR>2000</YR>
<VL>59</VL>
<NO>10</NO>
<PG>857-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bull-2007" MODIFIED="2011-11-04 14:50:42 +0100" MODIFIED_BY="[Empty name]" NAME="Bull 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bull KS, Spoudeas HA, Yadegarfar G, Kennedy CR</AU>
<TI>Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: a follow-up study in PNET3 trial survivors-on behalf of the CCLG (formerly UKCCSG)</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>27</NO>
<PG>4239-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Copeland-1999" NAME="Copeland 1999" TYPE="JOURNAL_ARTICLE">
<AU>Copeland D, deMoor C, Moore B, Ater J</AU>
<TI>Neurocognitive development of children after a cerebellar tumor in infancy: a longitudinal study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>11</NO>
<PG>3476-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellison-2005" MODIFIED="2010-03-01 14:31:27 +0100" MODIFIED_BY="[Empty name]" NAME="Ellison 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, et al</AU>
<TI>Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>31</NO>
<PG>7951-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gajjar-2006" MODIFIED="2010-07-01 10:33:29 +0200" MODIFIED_BY="[Empty name]" NAME="Gajjar 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, et al</AU>
<TI>Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial</TI>
<SO>Lancet Oncology</SO>
<YR>2006</YR>
<VL>7</VL>
<PG>813-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gandola-2009" MODIFIED="2014-08-12 14:26:01 +0200" MODIFIED_BY="[Empty name]" NAME="Gandola 2009" TYPE="JOURNAL_ARTICLE">
<AU>Gandola L, Massimino M, Cefalo G, Solero C, Spreafico F, Pecori E, et al</AU>
<TI>Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>4</NO>
<PG>566-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geyer-2005" MODIFIED="2010-03-01 14:31:35 +0100" MODIFIED_BY="[Empty name]" NAME="Geyer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, et al</AU>
<TI>Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>7621-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giangaspero-1999" MODIFIED="2010-03-01 14:31:42 +0100" MODIFIED_BY="[Empty name]" NAME="Giangaspero 1999" TYPE="JOURNAL_ARTICLE">
<AU>Giangaspero F, Perilongo G, Fondelli MP, Brisigotti M, Carollo C, Burnelli R, et al</AU>
<TI>Medulloblastoma with extensive nodularity: a variant with favorable prognosis</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1999</YR>
<VL>91</VL>
<NO>6</NO>
<PG>971-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grill-2005" MODIFIED="2014-11-13 16:02:53 +0100" MODIFIED_BY="[Empty name]" NAME="Grill 2005" TYPE="JOURNAL_ARTICLE">
<AU>Grill J, Sainte-Rose C, Jouvet A, Gentet JC, Lejars O, Frappaz D, et al</AU>
<TI>Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children</TI>
<SO>Lancet Oncology</SO>
<YR>2005</YR>
<VL>6</VL>
<PG>573-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grotzer-2000" MODIFIED="2010-03-01 14:32:12 +0100" MODIFIED_BY="[Empty name]" NAME="Grotzer 2000" TYPE="JOURNAL_ARTICLE">
<AU>Grotzer MA, Janss AJ, Fung KM, Biegel JA, Sutton LN, Rorke LB, et al</AU>
<TI>TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>5</NO>
<PG>1027-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grotzer-2001" MODIFIED="2010-03-01 14:32:16 +0100" MODIFIED_BY="[Empty name]" NAME="Grotzer 2001" TYPE="JOURNAL_ARTICLE">
<AU>Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A, et al</AU>
<TI>MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma</TI>
<SO>Clinical Cancer Research</SO>
<YR>2001</YR>
<VL>7</VL>
<PG>2425-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gurney-2003" MODIFIED="2010-03-01 14:32:18 +0100" MODIFIED_BY="[Empty name]" NAME="Gurney 2003" TYPE="JOURNAL_ARTICLE">
<AU>Gurney J, Kadan-Lottick N, Packer R, Neglia J, Sklar C, Punyko J, et al</AU>
<TI>Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors</TI>
<SO>Cancer</SO>
<YR>2003</YR>
<VL>97</VL>
<NO>3</NO>
<PG>663-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2014-11-13 16:03:55 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="BOOK">
<AU>Higgins JPT, Green S, editors</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2005</YR>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2014-11-13 16:04:20 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0</SO>
<YR>2008</YR>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kortmann-2000" MODIFIED="2014-11-13 16:04:59 +0100" MODIFIED_BY="[Empty name]" NAME="Kortmann 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kortmann RD, Kühl J, Timmermann B, Mittler U, Urban C, Budach V, et al</AU>
<TI>Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT 91</TI>
<SO>International Journal of Radiation Oncology, Biology and Physics</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>2</NO>
<PG>269-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lachin-2000" MODIFIED="2010-05-20 13:22:59 +0200" MODIFIED_BY="[Empty name]" NAME="Lachin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lachin JM</AU>
<TI>Statistical considerations in the intent-to-treat principle</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2000</YR>
<VL>21</VL>
<PG>167-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-1991" MODIFIED="2010-05-20 13:23:59 +0200" MODIFIED_BY="[Empty name]" NAME="Lee 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB</AU>
<TI>Analysis of clinical trials by treatment actually received: is it really an option?</TI>
<SO>Statistics in Medicine</SO>
<YR>1991</YR>
<VL>10</VL>
<PG>1595-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Livesey-1990" MODIFIED="2010-03-01 14:32:28 +0100" MODIFIED_BY="[Empty name]" NAME="Livesey 1990" TYPE="JOURNAL_ARTICLE">
<AU>Livesey EA, Hindmarsh PC, Brook CG, Whitton AC, Bloom HJ, Tobias JS, et al</AU>
<TI>Endocrine disorders following treatment of childhood brain tumours</TI>
<SO>British Journal of Cancer</SO>
<YR>1990</YR>
<VL>61</VL>
<PG>622-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Merchant-2008" MODIFIED="2011-08-10 15:25:29 +0200" MODIFIED_BY="[Empty name]" NAME="Merchant 2008" TYPE="JOURNAL_ARTICLE">
<AU>Merchant TE, Kun LE, Krasin MJ, Wallace D, Chintagumpala MM, Woo SY, et al</AU>
<TI>Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma</TI>
<SO>International Journal of Radiation Oncology, Biology and Physics</SO>
<YR>2008</YR>
<VL>70</VL>
<NO>3</NO>
<PG>782-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Northcott-2011" MODIFIED="2012-03-23 11:12:01 +0100" MODIFIED_BY="[Empty name]" NAME="Northcott 2011" TYPE="JOURNAL_ARTICLE">
<AU>Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S</AU>
<TI>Medulloblastoma comprises four distinct molecular variants</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>11</NO>
<PG>1408-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oyharcabal_x002d_Bourden-2005" MODIFIED="2011-08-10 15:31:20 +0200" MODIFIED_BY="[Empty name]" NAME="Oyharcabal-Bourden 2005" TYPE="JOURNAL_ARTICLE">
<AU>Oyharcabal-Bourden V, Kalifa C, Gentet JC, Frappaz D, Edan C, Chastagner P, et al</AU>
<TI>Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>19</NO>
<PG>4726-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Packer-2006" MODIFIED="2010-03-01 14:32:38 +0100" MODIFIED_BY="[Empty name]" NAME="Packer 2006" TYPE="JOURNAL_ARTICLE">
<AU>Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, et al</AU>
<TI>Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>25</NO>
<PG>4202-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Packer-2010" MODIFIED="2013-08-20 12:29:57 +0200" MODIFIED_BY="[Empty name]" NAME="Packer 2010" TYPE="JOURNAL_ARTICLE">
<AU>Packer RJ, Holmes E, Zhou T, Gajjar A, Vezina G</AU>
<TI>Second malignant neoplasms (SMNS) following &#8216;successful&#8217; treatment of non-disseminated medulloblastoma (MB): a 10-year follow-up of patients treated on a COG study</TI>
<SO>Neuro-Oncology</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>6</NO>
<PG>ii8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmer-2001" MODIFIED="2010-03-01 14:33:47 +0100" MODIFIED_BY="[Empty name]" NAME="Palmer 2001" TYPE="JOURNAL_ARTICLE">
<AU>Palmer S, Goloubeva O, Reddick W, Glass J, Gajjar A, Kun L, et al</AU>
<TI>Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>8</NO>
<PG>2302-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pfister-2009" MODIFIED="2012-04-29 18:02:28 +0200" MODIFIED_BY="[Empty name]" NAME="Pfister 2009" TYPE="JOURNAL_ARTICLE">
<AU>Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, et al</AU>
<TI>Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>10</NO>
<PG>1627-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-P_x00e9_rez_x002d_Martinez-2004" NAME="Pérez-Martinez 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pérez-Martinez A, Quintero V, Vicent MG, Sevilla J, Diaz MA, Madero L</AU>
<TI>High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors</TI>
<SO>Journal of Neuro-Oncology</SO>
<YR>2004</YR>
<VL>67</VL>
<PG>101-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2014-11-13 16:06:17 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rutkowski-2005" MODIFIED="2010-03-01 14:33:58 +0100" MODIFIED_BY="[Empty name]" NAME="Rutkowski 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, et al</AU>
<TI>Treatment of early childhood medulloblastoma by postoperative chemotherapy alone</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>352</VL>
<PG>978-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rutkowski-2007" MODIFIED="2014-11-13 16:06:37 +0100" MODIFIED_BY="[Empty name]" NAME="Rutkowski 2007" TYPE="JOURNAL_ARTICLE">
<AU>Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F, et al</AU>
<TI>Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91</TI>
<SO>Clinical Cancer Research</SO>
<YR>2007</YR>
<VL>13(9)</VL>
<PG>2651-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rutkowski-2010" MODIFIED="2014-08-15 18:02:34 +0200" MODIFIED_BY="[Empty name]" NAME="Rutkowski 2010" TYPE="JOURNAL_ARTICLE">
<AU>Rutkowski S, Von Hoff K, Emser A, Zwiener I, Pietsch T, Figarella-Branger D, et al</AU>
<TI>Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>33</NO>
<PG>4961-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shalet-1977" NAME="Shalet 1977" TYPE="JOURNAL_ARTICLE">
<AU>Shalet SM, Beardwell CG, MacFarlane IA, Jones PH, Pearsen D</AU>
<TI>Endocrine morbidity in adults treated with cerebral irradiation for brain tumours during childhood</TI>
<SO>Acta Endocrinologica</SO>
<YR>1977</YR>
<VL>84</VL>
<PG>673-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spoudeas-2003" NAME="Spoudeas 2003" TYPE="JOURNAL_ARTICLE">
<AU>Spoudeas H, Charmandari E, Brook C</AU>
<TI>Hypothalamo-pituitary-adrenal axis integrity after cranial irradiation for childhood posterior fossa tumours</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>2003</YR>
<VL>40</VL>
<PG>224-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-2012" MODIFIED="2012-08-15 14:28:26 +0200" MODIFIED_BY="[Empty name]" NAME="Taylor 2012" TYPE="JOURNAL_ARTICLE">
<AU>Taylor MD, Northcott PA, Korshunov A, Remke M, Cho Y, Clifford SC, et al</AU>
<TI>Molecular subgroups of medulloblastoma: the current consensus</TI>
<SO>Acta Neuropathologica</SO>
<YR>2012</YR>
<VL>123</VL>
<PG>465-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zeltzer-1999" MODIFIED="2014-11-13 16:06:55 +0100" MODIFIED_BY="[Empty name]" NAME="Zeltzer 1999" TYPE="JOURNAL_ARTICLE">
<AU>Zeltzer PM, Boyet JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al</AU>
<TI>Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>3</NO>
<PG>832-45</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-11-13 16:05:30 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Michiels-2007" MODIFIED="2014-11-13 16:05:30 +0100" MODIFIED_BY="[Empty name]" NAME="Michiels 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Michiels EMC, Schouten-Van Meeteren AYN, Doz F, van Dalen EC</AU>
<TI>Chemotherapy for children with medulloblastoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006678"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-11-17 11:43:05 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-11-17 11:43:05 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-11-13 15:30:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abd-El_x002d_Aal-2005">
<CHAR_METHODS MODIFIED="2014-11-13 15:29:06 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-13 15:29:41 +0100" MODIFIED_BY="[Empty name]">
<P>48 children with high-risk medulloblastoma (defined as &#8805; 1 of: positive cerebrospinal fluid, T3 and T4 lesions, &lt; 4 years of age and ependymal or glial differentiation)</P>
<P>10 stage M1 children (6 in experimental arm (i.e. RT and chemotherapy); 4 in standard arm (i.e. RT)); no further information on stage was provided, but absence of metastases was an eligibility criterion</P>
<P>Primary disease nm</P>
<P>30 classic medulloblastoma (18 in experimental arm; 12 in standard arm) and 18 desmoplastic medulloblastoma (9 in experimental arm; 9 in standard arm)</P>
<P>Molecular markers nm</P>
<P>Mean age in both the experimental and standard arm 7 years</P>
<P>32 boys (17 in experimental arm; 15 in standard arm) and 16 girls (10 in experimental arm; 6 in standard arm)</P>
<P>Prior chemotherapy nm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-13 15:30:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<I>Design:</I>
</U> surgery followed by RT ± chemotherapy. If applicable, chemotherapy was given during and after RT. Randomisation: 27 children received chemotherapy; 21 children did not</P>
<P>
<U>
<I>Surgery:</I>
</U>
 23 incisional biopsies (15 in experimental arm; 8 in standard arm), 23 total tumour excisions (11 in experimental arm; 12 in standard arm) and 2 stereotactic biopsies (1 in each treatment arm)</P>
<P>
<U>
<I>Imaging:</I>
</U> all participants underwent postoperative craniospinal MRI (interval between surgery and MRI nm)</P>
<P>
<U>
<I>RT</I>
</U>
 (according to protocol; actual received doses nm): target volume (Gy): dose/dose per fraction: craniospinal: 36/nm, posterior fossa: 56/nm, spinal: 36/1.5. RT was given by cobalt machine</P>
<P>
<U>
<I>Chemotherapy</I>
</U> (according to protocol; actual received doses nm): vincristine during spinal RT (weekly 1.4 mg/m<SUP>2</SUP>) and after RT 4 cycles (given every 21 days) of etoposide (100 mg/m<SUP>2</SUP> on days 1-3, route of delivery nm) and cisplatinum (75 mg/m<SUP>2</SUP> on day 1, route of delivery nm)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-13 15:30:21 +0100" MODIFIED_BY="[Empty name]">
<P>OS (definition nm)</P>
<P>DFS (definition nm)</P>
<P>Adverse effects (according to the WHO grading criteria)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-13 15:30:25 +0100" MODIFIED_BY="[Empty name]">
<P>Length of follow-up nm (it was stated that some children were followed for 3 years)</P>
<P>Number of children who stopped chemotherapy or RT prematurely or who did not receive the full doses nm</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-13 15:34:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bailey-1995-CT-vs-no-CT">
<CHAR_METHODS MODIFIED="2014-11-13 15:30:27 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation was performed centrally using a minimising approach</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-13 15:31:10 +0100" MODIFIED_BY="[Empty name]">
<P>229 children with low-risk medulloblastoma. Participants defined as being at low risk for tumour recurrence if the tumour was totally (no visible residual tumour) or subtotally (a thin film of tumour left in the tumour bed) resected, the brain stem was not involved by the tumour and there was no evidence of metastatic disease within the CNS. Presence of tumour cells in the craniospinal fluid was not taken into account in assigning risk status</P>
<P>T stage nm; 115 stage M0, 17 either stage M2 or M3, 97 stage nm</P>
<P>Primary disease nm</P>
<P>Histological subtype nm</P>
<P>Molecular markers nm</P>
<P>Exact age nm, but to be eligible for inclusion participants had to be aged 0-16 years</P>
<P>Sex nm</P>
<P>No prior chemotherapy</P>
<P>Data for children in each treatment arm were not provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-13 15:32:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<I>Design:</I>
</U> surgery followed by RT ± chemotherapy. If applicable, chemotherapy given before RT. Randomisation: at least 74 children (total number nm) received chemotherapy; at least 76 children (total number nm) did not. Some of the low-risk children (153 children) underwent a second randomisation regarding the RT dose on the CSA</P>
<P>
<U>
<I>Surgery</I>:</U> attempts were made to remove as much of the tumour as possible (no data for children in the different treatment arms provided)</P>
<P>
<U>
<I>Imaging:</I>
</U>
 postoperative imaging (CT scans or myelography) not mandatory; they could be performed at the discretion of the centre and whenever tumour recurrence was suspected (no further data provided)</P>
<P>
<U>
<I>RT</I>
</U>
 (according to protocol; actual received doses nm for the 229 eligible children): target volume (Gy): dose/dose per fraction: craniospinal: 35 or 25/1.66 (depending on treatment arm children were assigned to while performing the second randomisation); tumour-bearing area: 55/2</P>
<P>In children &lt; 2 years of age (number nm) reduced doses were recommended (see Notes): CSA: 30-35/1.4 tumour dose: 40-45/1.4. The boost encompassed the whole posterior fossa with inclusion of the surgical scar. If children were randomised to RT only group, RT started as soon as possible after surgery and at least within 28 days; if children were randomised to the chemotherapy arm, RT commenced within 1 week of the third methotrexate infusion. RT was to be delivered by megavoltage equipment</P>
<P>
<U>
<I>Chemotherapy</I>
</U> (according to protocol; actual received doses nm for the 229 eligible children): vincristine (1.5 mg/m<SUP>2 </SUP>(maximum 2 g) intravenously on days 1, 8, 15, 22, 29 and 36), procarbazine (100 mg/m<SUP>2</SUP> orally on days 1-14), methotrexate (2 g/m<SUP>2</SUP> intravenously with 6-hour infusion on days 15, 22 and 29) and prednisolone (100 mg/m<SUP>2</SUP> on days 15, 22 and 29; route of delivery nm). Chemotherapy was given in a 6-week module before RT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-13 15:33:00 +0100" MODIFIED_BY="[Empty name]">
<P>EFS (an event was defined to have taken place if the participant either developed any type of recurrence including newly diagnosed metastases or progression of any residual tumour or died without any evidence of recurrence)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-13 15:34:05 +0100" MODIFIED_BY="[Empty name]">
<P>Length of follow-up nm (maximal follow-up was 78 months)</P>
<P>This study also included 135 high-risk children (definition: if the tumour was incompletely resected, i.e. the surgeon reported the presence of macroscopic residual disease at the end of the procedure, if there was evidence of invasive brain stem involvement or if metastatic disease was present within the CNS), but since these children all received chemotherapy after the end of RT, they were not eligible for inclusion in this review</P>
<P>Number of children who stopped chemotherapy or RT prematurely or who did not receive the full doses: nm for the 229 eligible participants.</P>
<P>In this article, it was stated that in children &lt; 2 years of age it was recommended to give reduced RT doses; however, the provided doses for CSRT were in some cases higher/equal to the doses given to older children. No explanation for this inconsistency was available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-13 15:36:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bailey-1995-RTvslowRT_x002f_CT">
<CHAR_METHODS MODIFIED="2014-11-13 15:34:06 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation was performed centrally using a minimising approach</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-13 15:34:26 +0100" MODIFIED_BY="[Empty name]">
<P>153/229 children with low-risk medulloblastoma included in the study of <LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK> underwent a second randomisation regarding the RT dose on the CSA; 76/153 children were eligible for the evaluation of standard-dose RT on the CSA without chemotherapy versus reduced-dose RT on the CSA and chemotherapy. Participant characteristics were not stated for only these 76 children. For details on all 229 children see <LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK> above</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-13 15:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<I>Design:</I>
</U> surgery followed by standard-dose RT on the CSA without chemotherapy versus reduced-dose RT on the CSA and chemotherapy (RT doses on the posterior fossa were similar in both treatment groups). If applicable, chemotherapy was given before RT. Randomisation: 40 children received standard-dose RT without chemotherapy; 36 children received reduced-dose RT and chemotherapy</P>
<P>
<U>
<I>Surgery</I>:</U> attempts were made to remove as much of the tumour as possible (no data for children in the different treatment arms provided)</P>
<P>
<U>
<I>Imaging:</I>
</U>
 postoperative imaging (CT scans or myelography) was not mandatory; they could be performed at the discretion of the centre and whenever tumour recurrence was suspected (no further data provided)</P>
<P>
<U>
<I>Standard-dose RT</I>
</U>
 (according to protocol; actual received doses nm for the 40 eligible children): target volume (Gy): dose/dose per fraction: CSA: 35/1.66, tumour-bearing area: 55/2. RT started as soon as possible after surgery and at least within 28 days. The boost encompassed the whole posterior fossa with inclusion of the surgical scar</P>
<P>
<U>
<I>Reduced-dose RT</I>
</U>
 (according to protocol; actual received doses nm for the 36 eligible children): CSA: 25/1.66, tumour-bearing area: 55/2.</P>
<P>In children &lt; 2 years of age (number nm), reduced doses were recommended (see notes): CSA: 30-35/1.4, tumour: 40-45/1.4. RT commenced within 1 week of the third methotrexate infusion. The boost encompassed the whole posterior fossa with inclusion of the surgical scar</P>
<P>
<U>
<I>Chemotherapy</I>:</U> vincristine (1.5 mg/m<SUP>2 </SUP>(maximum 2 g) intravenously on days 1, 8, 15, 22, 29 and 36), procarbazine (100 mg/m<SUP>2</SUP> orally on days 1-14), methotrexate (2 g/m<SUP>2</SUP> intravenously with a 6-hour infusion on days 15, 22 and 29) and prednisolone (100 mg/m<SUP>2</SUP> on days 15, 22 and 29; route of delivery nm). Chemotherapy was given in a 6-week module before RT</P>
<P>RT was to be delivered by megavoltage equipment. No HART</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-13 15:35:47 +0100" MODIFIED_BY="[Empty name]">
<P>EFS (an event was defined to have taken place if the participant either developed any type of recurrence including newly diagnosed metastases or progression of any residual tumour or died without any evidence of recurrence)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-13 15:36:17 +0100" MODIFIED_BY="[Empty name]">
<P>Length of follow-up nm (maximal follow-up was 78 months)</P>
<P>Number of children who stopped chemotherapy or RT prematurely or who did not receive the full doses: nm for the 76 eligible children</P>
<P>In this article, it was stated that in children &lt; 2 years of age it was recommended to give reduced RT doses; however, the provided doses for CSRT were in some cases higher/equal to the doses given to older children. No explanation for this inconsistency was available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-17 11:43:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-1990">
<CHAR_METHODS MODIFIED="2014-11-13 15:36:17 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear (stratified by stage of medulloblastoma)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-17 11:43:05 +0100" MODIFIED_BY="[Empty name]">
<P>233 children with medulloblastoma</P>
<P>11 stage T1, 68 stage T2, 130 stage T3 and 24 stage T4; 191 stage M0 (see notes), 19 stage M1, 15 stage M2, 8 stage M3; children with stage M4 were not eligible for this study</P>
<P>Primary disease</P>
<P>Histological subtype nm</P>
<P>Molecular markers nm</P>
<P>Age range &lt; 2 years to &#8805; 16 years</P>
<P>154 boys and 79 girls</P>
<P>No prior chemotherapy; corticosteroids were allowed</P>
<P>191 children were randomised, whereas 42 children were not; data for children in each treatment arm nm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-13 15:38:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<I>Design:</I>
</U> surgery followed by RT ± chemotherapy. If applicable, chemotherapy was given during and after RT. Randomisation: 115 children received chemotherapy, including 6 children who switched from the other arm and 21 non-randomised children; 118 children received no chemotherapy, including 6 children who switched from the other arm and 21 non-randomised children</P>
<P>
<U>
<I>Surgery:</I>
</U> as extensive a resection as was compatible with subsequent good neurological function. There were 93 total resections, 105 subtotal resections (defined as 50-99%) and 33 partial resections (defined as &lt; 50%); for the other 2 children it was not known; data for children in each treatment arm nm</P>
<P>
<U>
<I>Imaging:</I>
</U>
 a postoperative CT scan was not required</P>
<P>
<U>
<I>RT</I>:</U> according to protocol: target volume (Gy): dose/dose per fraction: craniospinal: 35-40/1.6-2.0 (&#8804; 3 years: reduction of 5 Gy), posterior fossa: 50-55/1.6-2.0 (&#8804; 3 years: reduction of 5 Gy), localised spinal metastases: 50/nm. Of 220 children for whom posterior fossa data were reviewed, 74% received the protocol dose, 14% less and 12% more; 62% received the protocol dose to the brain, 15% less than 35 Gy and 23% more than 40 Gy; 66% received the protocol dose to the spine, 26% less than 35 Gy and 8% more than 40 Gy</P>
<P>
<U>
<I>Chemotherapy</I>
</U> (according to protocol; actual received doses nm: see notes): vincristine (1.5 mg/m<SUP>2</SUP> intravenously on day 1 of each week of RT and on day 1 of first 3 weeks of each chemotherapy cycle), CCNU (100 mg/m<SUP>2</SUP> orally on day 1 of each chemotherapy cycle) and prednisone (40 mg/m<SUP>2</SUP>/day orally for 14 days on day 1 of each chemotherapy cycle). There were 8 cycles (every 6 weeks) starting 4 weeks following the completion of RT (= 3 months since start of RT)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-13 15:38:51 +0100" MODIFIED_BY="[Empty name]">
<P>EFS (defined as alive without sepsis or disease recurrence or progression)</P>
<P>Adverse effects (nm on which criteria they were based)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-13 15:39:19 +0100" MODIFIED_BY="[Empty name]">
<P>Length of follow-up nm (maximal follow-up was 10 years)</P>
<P>Number of children who stopped chemotherapy prematurely or who did not receive the full doses: nm, but 60% of reviewed children received &#8805; 75% of the recommended dose in every therapy course received</P>
<P>ITT analyses were not possible, since 42 children were not randomised (21 in each treatment arm) and 12 children switched between treatment arms after randomisation (6 in each treatment arm)</P>
<P>Data presented in this table were for all 233 children; no separate data for the randomised children only were presented</P>
<P>All staging was done based on surgeon's impression. As stated by the authors: it is likely that the M0 group included children with stage M0 to M3 since cytology data were reported in only 56% of the M0 children and an initial myelogram was performed in only 11% of M0 children. However, the surgical check sheet classified the children as M0</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-13 15:40:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krischer-1991">
<CHAR_METHODS MODIFIED="2014-11-13 15:39:46 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear (balanced by treatment institution and participant age at diagnosis (&#8804; 4 years and &#8805; 5 years))</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-13 15:40:00 +0100" MODIFIED_BY="[Empty name]">
<P>71 children with medulloblastoma</P>
<P>29 stage T1 or T2 (15 in experimental arm (i.e. RT and chemotherapy); 14 in standard arm (i.e. RT)), 33 stage T3 (15 in experimental arm; 18 in standard arm) and 9 stage unknown (6 in experimental arm; 3 in standard arm); all children did not have metastases outside the CNS (number of children with stage M0-3 nm)</P>
<P>Primary disease</P>
<P>Histological subtype nm</P>
<P>Molecular markers nm</P>
<P>Age range &#8804; 4 years (13 in experimental arm; 12 in standard arm) to 20 years (23 in both arms)</P>
<P>48 males (25 in experimental arm; 23 in standard arm) and 23 females (11 in experimental arm; 12 in standard arm)</P>
<P>No prior chemotherapy (with the exception of corticosteroids)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-13 15:40:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<I>Design:</I>
</U> surgery followed by RT ± chemotherapy. If applicable, chemotherapy was given after RT. Randomisation: 36 children received chemotherapy; 35 children did not</P>
<P>
<U>
<I>Surgery</I>:</U> 51 subtotal excisions (28 in experimental arm; 23 in standard arm) and 20 total removals (8 in experimental arm; 12 in standard arm)</P>
<P>
<U>
<I>Imaging:</I>
</U>
 no postoperative imaging</P>
<P>
<U>
<I>RT</I>
</U>
 (according to protocol; actual received doses nm): target volume (Gy): dose/dose per fraction: cranial 35 Gy or 25 Gy (&lt; 3 years) (later modified to 40 Gy and 35.2 Gy (&lt; 3 years))/1.6-1.7, posterior fossa: 54-54.4 Gy or 48 Gy (&lt; 3 years)/1.6-1.7, spinal: 30 Gy or 25 Gy (&lt; 3 years)/1.6-1.7</P>
<P>
<U>
<I>Chemotherapy</I>
</U> (according to protocol; actual received doses nm): nitrogen mustard (3 mg/m<SUP>2</SUP> intravenously on days 1 and 8), vincristine (1.4 mg/m<SUP>2</SUP> intravenously on days 1 and 8), procarbazine (50 mg on day 1, 100 mg on day 2 and 100 mg/m<SUP>2</SUP> on days 3-10; route of administration nm) and prednisone (40 mg/m<SUP>2</SUP> orally on days 1-10) (i.e. MOPP). Chemotherapy started 4 weeks after the completion of RT and was repeated every 4 weeks for 12 courses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-13 15:40:48 +0100" MODIFIED_BY="[Empty name]">
<P>OS (definition nm)</P>
<P>EFS (defined as the time from start of treatment until disease progression or death, progression being an increase in measurable lesions or the development of recurrent or new lesions, as measured by CT scans of the brain or spinal imaging (or both) or the development of metastatic disease outside the CNS)</P>
<P>Adverse effects (definition unclear, but at least some based on WHO criteria)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-13 15:40:53 +0100" MODIFIED_BY="[Empty name]">
<P>Length of follow-up nm (maximal follow-up was 9 years)</P>
<P>Number of children who stopped chemotherapy or RT prematurely or who did not receive the full doses nm</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-13 15:42:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tait-1990">
<CHAR_METHODS MODIFIED="2014-11-13 15:40:54 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear (stratified according to age group, sex and extent of surgery)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-13 15:41:07 +0100" MODIFIED_BY="[Empty name]">
<P>286 children with medulloblastoma</P>
<P>113 stage T1 or T2, 163 stage T3 or T4 (91 in experimental arm, i.e. chemotherapy and RT; 72 in standard arm, i.e. RT) and 10 T-stage nm; for all children the M-stage was nm</P>
<P>Primary disease</P>
<P>Histological subtype nm</P>
<P>Molecular markers nm</P>
<P>Aged &lt; 2 to 15 years</P>
<P>208 boys and 78 girls</P>
<P>No previous therapy</P>
<P>Data for children in each treatment arm were not provided unless otherwise stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-13 15:42:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<I>Design:</I>
</U> surgery followed by RT ± chemotherapy. If applicable, chemotherapy was given during and after RT. Randomisation: 141 children received chemotherapy; 145 children did not</P>
<P>
<U>
<I>Surgery</I>: </U>as radical as possible without undue risk to life and function. 128 total resections, 111 subtotal resections and 39 partial resections; for the other 8 children it was nm; data for children in each treatment arm were not provided</P>
<P>
<U>
<I>Imaging</I>
</U>
<I>: </I>postoperative imaging nm</P>
<P>
<U>
<I>RT</I>
</U>
 (according to protocol; actual received doses nm: see notes): commencing as soon as possible following postoperative recovery, at least within 1 month of surgery. target volume (Gy): dose/dose per fraction: cranial: 35-45 in 7-8 weeks (&lt; 2 years: 30-35 Gy in 6-7 weeks), posterior fossa: 50-55 in 7-8 weeks (&lt; 2 years: 40-45 Gy), spinal: 30-35 in 5-6 weeks (&lt; 2 years: 30 Gy in 6 weeks). Treatment was daily, 5 days per week. Megavoltage or cobalt-60 equipment was used</P>
<P>
<U>
<I>Chemotherapy</I>
</U> (according to protocol; actual received doses nm: see notes): vincristine during RT (weekly injection 1 mg/m<SUP>2</SUP>) and 8 courses of maintenance therapy commencing 1 month after completing irradiation consisting of CCNU (100 mg/m<SUP>2</SUP> orally on day 1) and vincristine (1.5 mg/m<SUP>2</SUP> intravenously on days 1, 8 and 15). Chemotherapy courses were cycled every 6 weeks for 1 year</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-13 15:42:18 +0100" MODIFIED_BY="[Empty name]">
<P>DFS (defined as from time of operation to disease recurrence or death from other causes)</P>
<P>Adverse effects (definition nm)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-13 15:42:24 +0100" MODIFIED_BY="[Empty name]">
<P>Length of follow-up nm (maximal follow-up was 13 years)</P>
<P>Number of children who stopped chemotherapy or RT prematurely or who did not receive the full doses nm</P>
<P>For information on actual received chemotherapy and RT doses and for more information on adverse effects this article refers to a conference abstract, but the abstract book shows only an empty page (<LINK REF="REF-Bloom-1981" TYPE="REFERENCE">Bloom 1981</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-13 15:43:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taylor-2003_x002f_4">
<CHAR_METHODS MODIFIED="2014-11-13 15:42:31 +0100" MODIFIED_BY="[Empty name]">
<P>The randomisation procedure involved the responsible clinician telephoning the data centre where the children's details were entered in a computer program and using the minimisation technique (stratified by age (3-7, 8-11 and 12-16 years), extent of tumour resection (total or less than total) and treatment centre)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-13 15:42:48 +0100" MODIFIED_BY="[Empty name]">
<P>179 children with medulloblastoma</P>
<P>T stage nm; stage M0 or M1 (number of children in each treatment arm nm); the exact number of children with M1 was unclear since too few children had undergone lumbar craniospinal fluid sampling to categorise the stage as M0 or M1</P>
<P>Primary disease nm</P>
<P>Histological subtype nm</P>
<P>Molecular markers nm</P>
<P>Median age in experimental arm (i.e. RT and chemotherapy) 7.74 years (range 3.1 to 15 years); median age in standard arm (i.e. RT) 7.67 years (range 2.9 to 16.8 years)</P>
<P>111 boys (57 in experimental arm; 54 in standard arm) and 68 girls (33 in experimental arm; 35 in standard arm)</P>
<P>Previous therapy nm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-13 15:43:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<I>Design:</I>
</U> surgery followed by RT ± chemotherapy. If applicable, chemotherapy was given before RT. Randomisation: 90 children received chemotherapy; 89 children did not</P>
<P>
<U>
<I>Surgery</I>:</U> maximal safe tumour resection was recommended. 99 total resections (50 in experimental arm; 49 in standard arm), 79 less than total resections (40 in experimental arm; 39 in standard arm) and for 1 child (in standard arm) the extent of the resection was unknown (as assessed by the neurosurgeon)</P>
<P>
<U>
<I>Imaging:</I>
</U> postoperative imaging by cranial MRI or CT scan within 48-72 hours after surgery was mandatory; nm if all children indeed underwent cranial MRI or CT scan</P>
<P>
<U>
<I>RT:</I>
</U>
 starting within 4 weeks of surgery (in children randomised to no chemotherapy) or as soon as possible after count recovery (i.e. neutrophils &gt; 1 x 10<SUP>9</SUP>/L, platelets &gt; 100 x 10<SUP>9</SUP>/L) after the final cycle of chemotherapy. According to protocol, target volume (Gy): dose/dose per fraction: craniospinal 35/1.67, posterior fossa: 55/1.67. Treatment was daily, 5 days per week. RT was recommended to be completed within 50 days. Mean/median/range of actually received craniospinal dose in intervention group: 34.72 Gy, 35.03 Gy, 25.2-40.28 Gy (in 19 children, RT was not completed within 50 days); in control group: 34.57 Gy, 35.07 Gy, 15.03-40 Gy (in 23 children, RT was not completed within 50 days)</P>
<P>
<U>
<I>Chemotherapy</I>
</U>
 (according to protocol; actual received doses nm): alternating cycles of vincristine (1.5 mg/m<SUP>2 </SUP>on days 1, 7 and 14), etoposide (100 mg/m<SUP>2</SUP> on days 1, 2 and 3) and carboplatin (500 mg/m<SUP>2</SUP> on days 1 and 2) and vincristine (1.5 mg/m<SUP>2</SUP> on days 1, 7 and 14; day 1 only for cycle 4), etoposide (100 mg/m<SUP>2</SUP> on days 1, 2 and 3) and cyclophosphamide (1.5 mg/m<SUP>2 </SUP>on day 1), 4 cycles (all intravenously) at 3-week intervals. Chemotherapy was intended to begin within 28 days of surgery. Median time to complete chemotherapy was 78 days (shortest duration was 66 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-13 15:43:40 +0100" MODIFIED_BY="[Empty name]">
<P>OS (defined as the time from the date of diagnosis to the date of death)</P>
<P>EFS (defined as the time from the date of diagnosis to the date of the first event; an event was defined as recurrence or death)</P>
<P>Adverse effects (nm on which criteria they were based)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-13 15:43:54 +0100" MODIFIED_BY="[Empty name]">
<P>Median follow-up was 5.4 years (range 0.2 to 10 years)</P>
<P>3/179 children had a review diagnosis of ganglioneuroblastoma, which is a tumour with a PNET component. These children were not retrospectively withdrawn from the analyses</P>
<P>Number of children who stopped chemotherapy prematurely or who did not receive the full doses: 4 children. Number of children who stopped RT prematurely or who did not receive the full doses: 3 children received a CSRT dose of &lt; 30 Gy, 3 children received a PF dose of &lt; 50 Gy, no RT details available for 6 children</P>
<P>We tried to contact these authors regarding more information on the definition of EFS; however, we did not receive a reply</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-13 15:45:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Eys-1981">
<CHAR_METHODS MODIFIED="2014-11-13 15:43:56 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear (stratified by diagnosis (medulloblastoma versus ependymoma: see notes) and by the presence or absence of a ventriculoperitoneal or atrial shunt)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-13 15:44:34 +0100" MODIFIED_BY="[Empty name]">
<P>34 children with medulloblastoma</P>
<P>Stage nm</P>
<P>Primary disease</P>
<P>Histological subtype nm</P>
<P>Molecular markers nm</P>
<P>Age nm</P>
<P>Sex nm</P>
<P>No prior treatment (with the exception of glucocorticoids)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-13 15:44:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<I>Design:</I>
</U> surgery followed by RT ± chemotherapy. If applicable, chemotherapy was given after RT. Randomisation: 16 children received chemotherapy; 18 children did not</P>
<P>
<U>
<I>Surgery</I>:</U> as much tumour tissue as possible was resected</P>
<P>
<U>
<I>Imaging:</I>
</U>
 postoperative imaging nm</P>
<P>
<U>
<I>RT</I>
</U>
 (according to protocol; actual received doses nm) started as soon as the surgical wound has healed, usually within 10 days. Target volume (Gy): dose/dose per fraction: cranial: 40/nm or 35/nm (&lt; 3 years), posterior fossa: 50/nm or 45/nm (&lt; 3 years), spinal: 30/nm or 25/nm (&lt; 3 years). RT was done with megavoltage equipment</P>
<P>
<U>
<I>Chemotherapy</I>
</U> (according to protocol; actual received doses nm): vincristine (2 mg/m<SUP>2</SUP> intravenously; with a maximum dose of 2 mg), methotrexate (15 mg/m<SUP>2</SUP> intrathecally; no maximum dose) and hydrocortisone (15 mg/m<SUP>2</SUP> intrathecally; no maximum dose). Initially chemotherapy was started on the first week after RT, with all 3 drugs given weekly for 4 doses and then every 4 weeks thereafter for 12 doses (total course 52 weeks). Doses were delayed for toxicity but not decreased. However, serious toxicity with myelosuppression was observed in this schedule. Therefore, it was altered to give vincristine as above, for 4 doses starting the first week after RT, followed by vincristine and methotrexate plus hydrocortisone weekly for 4 doses. Then the treatment was given every 4 weeks as above</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-13 15:44:54 +0100" MODIFIED_BY="[Empty name]">
<P>OS (definition nm)</P>
<P>Adverse effects (nm on which criteria they were based)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-13 15:45:03 +0100" MODIFIED_BY="[Empty name]">
<P>In this review, only children with medulloblastoma were included. There were 34 evaluable children, but it is unclear how many children with medulloblastoma were originally included in this study</P>
<P>Length of follow-up nm (maximal follow-up was 24 months)</P>
<P>Number of children who stopped chemotherapy or RT prematurely or who did not receive the full doses nm</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CCNU: lomustine; CNS: central nervous system; CSA: craniospinal axis; CSRT: craniospinal radiotherapy; CT: computed tomography; DFS: disease-free survival; EFS: event-free survival; Gy: gray; HART: hyperfractionated accelerated radiotherapy; ITT: intention to treat; MOPP: mechlorethamine, vincristine, procarbazine and prednisone; MRI: magnetic resonance imaging; nm: not mentioned; OS: overall survival; PNET: primitive neuroectodermal tumour; RT: radiotherapy; WHO: World Health Organization.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-11-13 15:46:58 +0100" MODIFIED_BY="[Empty name]" SORT_BY="YEAR">
<EXCLUDED_CHAR MODIFIED="2014-11-13 15:46:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neidhardt-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-13 15:46:52 +0100" MODIFIED_BY="[Empty name]">
<P>All participants received chemotherapy. They were randomised for maintenance chemotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-13 15:46:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neidhardt-1987b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-13 15:46:53 +0100" MODIFIED_BY="[Empty name]">
<P>Description of the design of the <LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK>; <LINK REF="STD-Bailey-1995-RTvslowRT_x002f_CT" TYPE="STUDY">Bailey 1995 RTvslowRT/CT</LINK> study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-13 15:46:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neidhardt-1987a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-13 15:46:54 +0100" MODIFIED_BY="[Empty name]">
<P>Preliminary results of a study included in this review (<LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK>; <LINK REF="STD-Bailey-1995-RTvslowRT_x002f_CT" TYPE="STUDY">Bailey 1995 RTvslowRT/CT</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-13 15:46:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rogers-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-13 15:46:58 +0100" MODIFIED_BY="[Empty name]">
<P>Participants treated according to the same protocol as <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK> and overlap with participants in the <LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK> is likely; the primary outcome of this review (i.e. survival) was not presented and only a very small subgroup of eligible participants (26%) was described with regard to alopecia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-11-12 17:46:17 +0100" MODIFIED_BY="Anne Lawson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-11-12 17:46:17 +0100" MODIFIED_BY="Anne Lawson" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-11-12 17:46:17 +0100" MODIFIED_BY="Anne Lawson" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-11-12 17:46:17 +0100" MODIFIED_BY="Anne Lawson" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-11-12 17:46:17 +0100" MODIFIED_BY="Anne Lawson" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-11-12 17:46:17 +0100" MODIFIED_BY="Anne Lawson" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-11-12 17:46:17 +0100" MODIFIED_BY="Anne Lawson" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2014-11-12 15:59:04 +0100" MODIFIED_BY="Anne Lawson" NO="7">
<NAME>Blinding of care providers</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2014-11-12 15:59:04 +0100" MODIFIED_BY="Anne Lawson" NO="8">
<NAME>Blinding of patients</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2014-11-12 15:59:04 +0100" MODIFIED_BY="Anne Lawson" NO="9">
<NAME>Blinding of outcome assessors (EFS/DFS)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2014-11-12 15:59:04 +0100" MODIFIED_BY="Anne Lawson" NO="10">
<NAME>Blinding of outcome assessors (adverse effects)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2014-11-12 15:59:04 +0100" MODIFIED_BY="Anne Lawson" NO="11">
<NAME>Intention-to-treat analysis (EFS/DFS)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2014-11-12 15:59:04 +0100" MODIFIED_BY="Anne Lawson" NO="12">
<NAME>Intention-to-treat analysis (OS)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2014-11-12 15:59:04 +0100" MODIFIED_BY="Anne Lawson" NO="13">
<NAME>Intention-to-treat analysis (adverse effects)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="STUDY" MODIFIED="2014-11-12 15:59:04 +0100" MODIFIED_BY="Anne Lawson" NO="14">
<NAME>Completeness of follow-up (EFS/DFS)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-15" LEVEL="STUDY" MODIFIED="2014-11-12 15:59:04 +0100" MODIFIED_BY="Anne Lawson" NO="15">
<NAME>Completeness of follow-up (OS)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-16" LEVEL="STUDY" MODIFIED="2014-11-12 15:59:04 +0100" MODIFIED_BY="Anne Lawson" NO="16">
<NAME>Completeness of follow-up (adverse effects)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-17" LEVEL="GROUP" NO="17">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-18" LEVEL="GROUP" NO="18">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2014-11-13 15:51:03 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-11-13 15:49:04 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-10-07 11:14:44 +0200" MODIFIED_BY="[Empty name]">Criteria for the assessment of risk of bias in included studies</TITLE>
<TABLE COLS="3" ROWS="7">
<TR>
<TD>
<P>
<B>Risk of bias item</B>
</P>
</TD>
<TD>
<P>
<B>Type of bias</B>
</P>
</TD>
<TD>
<P>
<B>Implementation</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Allocation concealment</P>
</TD>
<TD>
<P>Selection bias</P>
</TD>
<TD>
<P>
<I>Adequate</I>: use of randomisation method that did not allow investigator and participant to know or influence the allocation of treatment before eligible participants entered the study<BR/>
<I>Inadequate</I>: use of alternate medical record numbers or unsealed envelopes as randomisation method, or there was information in the study indicating that investigators or participants could have influenced the allocation of treatment, or both<BR/>
<I>Unclear</I>: randomisation stated but no information on method used was available</P>
</TD>
</TR>
<TR>
<TD>
<P>Blinding of care providers</P>
</TD>
<TD>
<P>Performance bias</P>
</TD>
<TD>
<P>Adequate information about blinding must have been provided</P>
</TD>
</TR>
<TR>
<TD>
<P>Blinding of participants</P>
</TD>
<TD>
<P>Performance bias</P>
</TD>
<TD>
<P>Adequate information about blinding must have been provided</P>
</TD>
</TR>
<TR>
<TD>
<P>Blinding of outcome assessors</P>
</TD>
<TD>
<P>Detection bias</P>
</TD>
<TD>
<P>Adequate information about blinding must have been provided</P>
</TD>
</TR>
<TR>
<TD>
<P>Intention-to-treat analysis</P>
</TD>
<TD>
<P>Attrition bias</P>
</TD>
<TD>
<P>
<I>Yes</I>: all participants were analysed in the treatment group to which they were randomised, regardless of whether or not they received the allocated intervention<BR/>
<I>No</I>: some participants (&lt; 5%, 5-10%, 11-20%, &gt; 20%) were not analysed in the treatment group to which they were randomised because they did not receive study intervention, they withdrew from the study or because of protocol violation<BR/>
<I>Unclear</I>: inability to determine if participants were analysed according to the intention-to-treat principle</P>
</TD>
</TR>
<TR>
<TD>
<P>Completeness of follow-up</P>
</TD>
<TD>
<P>Attrition bias</P>
</TD>
<TD>
<P>Percentage of participants excluded or lost to follow-up (&lt; 5%, 5-10%, 11-20%, &gt; 20%) should be stated</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2014-11-13 15:51:03 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-10-07 11:23:02 +0200" MODIFIED_BY="[Empty name]">Risk of bias in included studies</TITLE>
<TABLE COLS="8" ROWS="9">
<TR>
<TD>
<P>
<B>Study</B>
</P>
</TD>
<TD>
<P>
<B>Comparison</B>
</P>
</TD>
<TD>
<P>
<B>Allocation concealment</B>
</P>
</TD>
<TD>
<P>
<B>Blinding of care providers</B>
</P>
</TD>
<TD>
<P>
<B>Blinding of participants</B>
</P>
</TD>
<TD>
<P>
<B>Blinding of outcome assessors</B>
</P>
</TD>
<TD>
<P>
<B>Intention-to-treat analysis</B>
</P>
</TD>
<TD>
<P>
<B>Completeness of follow-up</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Abd-El_x002d_Aal-2005" TYPE="STUDY">Abd El-Aal 2005</LINK>
</P>
</TD>
<TD>
<P>Chemotherapy vs. no chemotherapy</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>DFS and adverse effects: unclear</P>
</TD>
<TD>
<P>OS, DFS and adverse effects: unclear</P>
</TD>
<TD>
<P>OS, DFS and adverse effects: unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bailey-1995-CT-vs-no-CT" TYPE="STUDY">Bailey 1995 CT vs no CT</LINK>
</P>
</TD>
<TD>
<P>Chemotherapy vs. no chemotherapy</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>EFS: unclear</P>
</TD>
<TD>
<P>EFS: yes</P>
</TD>
<TD>
<P>EFS: unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Evans-1990" TYPE="STUDY">Evans 1990</LINK>
</P>
</TD>
<TD>
<P>Chemotherapy vs. no chemotherapy</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>EFS and adverse effects: unclear</P>
</TD>
<TD>
<P>EFS and adverse effects: unclear</P>
</TD>
<TD>
<P>EFS and adverse effects: unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Krischer-1991" TYPE="STUDY">Krischer 1991</LINK>
</P>
</TD>
<TD>
<P>Chemotherapy vs. no chemotherapy</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>EFS and adverse effects: unclear</P>
</TD>
<TD>
<P>OS, EFS and adverse effects: unclear</P>
</TD>
<TD>
<P>OS, EFS and adverse effects: unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tait-1990" TYPE="STUDY">Tait 1990</LINK>
</P>
</TD>
<TD>
<P>Chemotherapy vs. no chemotherapy</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>DFS and adverse effects: unclear</P>
</TD>
<TD>
<P>DFS and adverse effects: yes</P>
</TD>
<TD>
<P>DFS and adverse effects: no</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Taylor-2003_x002f_4" TYPE="STUDY">Taylor 2003/4</LINK>
</P>
</TD>
<TD>
<P>Chemotherapy vs. no chemotherapy</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>EFS and adverse effects: unclear</P>
</TD>
<TD>
<P>OS, EFS and adverse effects: unclear</P>
</TD>
<TD>
<P>OS, EFS and adverse effects: unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Van-Eys-1981" TYPE="STUDY">Van Eys 1981</LINK>
</P>
</TD>
<TD>
<P>Chemotherapy vs. no chemotherapy</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not applicable for OS</P>
</TD>
<TD>
<P>OS: unclear</P>
</TD>
<TD>
<P>OS: unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bailey-1995-RTvslowRT_x002f_CT" TYPE="STUDY">Bailey 1995 RTvslowRT/CT</LINK>
</P>
</TD>
<TD>
<P>Standard-dose radiotherapy without chemotherapy vs. reduced-dose radiotherapy and chemotherapy</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>EFS: unclear</P>
</TD>
<TD>
<P>EFS: yes</P>
</TD>
<TD>
<P>EFS: unclear</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>DFS: disease-free survival; EFS: event-free survival; OS: overall survival.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-11-13 16:10:41 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-11-13 16:10:04 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Treatment including chemotherapy versus treatment not including chemotherapy</NAME>
<IV_OUTCOME CHI2="6.1986095018673035" CI_END="0.9814298800576675" CI_START="0.6846167736910437" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.8196971136273863" ESTIMABLE="YES" I2="19.336748048190934" I2_Q="33.43827111759967" ID="CMP-001.01" LOG_CI_END="-0.008140723870264668" LOG_CI_START="-0.16455246448499572" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.08634659417763021" MODIFIED="2014-11-13 16:08:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.28737038583106933" P_Q="0.21165866120062748" P_Z="0.030465613960797385" Q="4.507094467603641" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.013421665362932392" TOTALS="SUB" TOTAL_1="0" TOTAL_2="0" WEIGHT="400.0" Z="2.1639835233687337">
<NAME>Event-free survival/disease-free survival (EFS/DFS)</NAME>
<GROUP_LABEL_1>Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>No chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chemotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no chemotherapy</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.9978413383702105" CI_END="1.474486656713719" CI_START="0.7026191883281787" DF="1" EFFECT_SIZE="1.0178421380257958" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.16864084678146038" LOG_CI_START="-0.15327999392450456" LOG_EFFECT_SIZE="0.0076804264284779395" MODIFIED="2011-01-21 11:12:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.31783365488484894" P_Z="0.9254887802646687" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999999" Z="0.09352211650985151">
<NAME>EFS including progression</NAME>
<IV_DATA CI_END="1.7527606804039244" CI_START="0.7399356347763881" EFFECT_SIZE="1.1388283833246218" ESTIMABLE="YES" ESTIMATE="0.13" LOG_CI_END="0.243722622154691" LOG_CI_START="-0.13080605685984556" LOG_EFFECT_SIZE="0.05645828264742272" MODIFIED="2011-01-21 11:12:40 +0100" MODIFIED_BY="[Empty name]" ORDER="10" SE="0.22" STUDY_ID="STD-Bailey-1995-CT-vs-no-CT" TOTAL_1="0" TOTAL_2="0" WEIGHT="73.88019427954667"/>
<IV_DATA CI_END="1.5298759815060854" CI_START="0.3587294935853226" EFFECT_SIZE="0.7408182206817179" ESTIMABLE="YES" ESTIMATE="-0.3" LOG_CI_END="0.18465622641852114" LOG_CI_START="-0.4452329155604723" LOG_EFFECT_SIZE="-0.13028834457097555" MODIFIED="2010-08-20 14:53:03 +0200" MODIFIED_BY="[Empty name]" ORDER="6" SE="0.37" STUDY_ID="STD-Krischer-1991" TOTAL_1="0" TOTAL_2="0" WEIGHT="26.119805720453318"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.693673695893452" CI_END="0.9068513359504045" CI_START="0.5449373116021944" DF="1" EFFECT_SIZE="0.7029773318078414" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.04246390287180451" LOG_CI_START="-0.26365345513831445" LOG_EFFECT_SIZE="-0.15305867900505943" MODIFIED="2010-08-20 14:53:03 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.40491803035759233" P_Z="0.006677565329920233" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="2.712510562069749">
<NAME>EFS/DFS not including progression</NAME>
<IV_DATA CI_END="1.0040025867204487" CI_START="0.5576662590026755" EFFECT_SIZE="0.7482635675785652" ESTIMABLE="YES" ESTIMATE="-0.29" LOG_CI_END="0.0017348317302853331" LOG_CI_START="-0.2536256312341715" LOG_EFFECT_SIZE="-0.12594539975194305" MODIFIED="2010-08-20 14:53:03 +0200" MODIFIED_BY="[Empty name]" ORDER="20" SE="0.15" STUDY_ID="STD-Tait-1990" TOTAL_1="0" TOTAL_2="0" WEIGHT="75.02774694783574"/>
<IV_DATA CI_END="0.9700483493661088" CI_START="0.35008103035982935" EFFECT_SIZE="0.5827482523739896" ESTIMABLE="YES" ESTIMATE="-0.54" LOG_CI_END="-0.013206618991893484" LOG_CI_START="-0.45583142146361855" LOG_EFFECT_SIZE="-0.234519020227756" MODIFIED="2010-08-20 14:53:03 +0200" MODIFIED_BY="[Empty name]" ORDER="21" SE="0.26" STUDY_ID="STD-Taylor-2003_x002f_4" TOTAL_1="0" TOTAL_2="0" WEIGHT="24.972253052164262"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="4.705729984530595" CI_START="0.5893229686107733" DF="0" EFFECT_SIZE="1.6652911949458864" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.6726270036745321" LOG_CI_START="-0.2296466321332152" LOG_EFFECT_SIZE="0.22149018577065846" MODIFIED="2010-08-20 14:53:03 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.33591694394964633" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="0.9622641509433962">
<NAME>Definition of DFS not provided</NAME>
<IV_DATA CI_END="4.705729984530595" CI_START="0.5893229686107733" EFFECT_SIZE="1.6652911949458864" ESTIMABLE="YES" ESTIMATE="0.51" LOG_CI_END="0.6726270036745321" LOG_CI_START="-0.2296466321332152" LOG_EFFECT_SIZE="0.22149018577065846" MODIFIED="2010-08-20 14:53:03 +0200" MODIFIED_BY="[Empty name]" ORDER="22" SE="0.53" STUDY_ID="STD-Abd-El_x002d_Aal-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.2121469874439317" CI_START="0.5755707297035232" DF="0" EFFECT_SIZE="0.835270211411272" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.08355528646823734" LOG_CI_START="-0.23990129995340798" LOG_EFFECT_SIZE="-0.07817300674258534" MODIFIED="2014-11-13 16:08:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.343451088390867" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="0.9473684210526315">
<NAME>EFS in participants without sepsis</NAME>
<IV_DATA CI_END="1.2121469874439317" CI_START="0.5755707297035232" EFFECT_SIZE="0.835270211411272" ESTIMABLE="YES" ESTIMATE="-0.18" LOG_CI_END="0.08355528646823734" LOG_CI_START="-0.23990129995340798" LOG_EFFECT_SIZE="-0.07817300674258534" MODIFIED="2010-08-20 14:53:03 +0200" MODIFIED_BY="[Empty name]" ORDER="23" SE="0.19" STUDY_ID="STD-Evans-1990" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.434228611368046" CI_END="1.6745410590744172" CI_START="0.6733470979070402" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="1.061860330954095" ESTIMABLE="YES" I2="12.644138189596772" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.22389580073276008" LOG_CI_START="-0.17176100732654423" LOG_DATA="YES" LOG_EFFECT_SIZE="0.026067396703107922" MODIFIED="2011-01-21 11:11:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.32939327167237287" P_Q="1.0" P_Z="0.7962062741273513" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.03015364379814546" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="0.25825997515074606">
<NAME>Overall survival</NAME>
<GROUP_LABEL_1>Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>No chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chemotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no chemotherapy</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="7.801975338082145" CI_START="0.6348433838567672" EFFECT_SIZE="2.225540928492468" ESTIMABLE="YES" ESTIMATE="0.8" LOG_CI_END="0.8922045731801093" LOG_CI_START="-0.19733340213490633" LOG_EFFECT_SIZE="0.3474355855226015" MODIFIED="2010-04-07 14:30:17 +0200" MODIFIED_BY="[Empty name]" ORDER="1" SE="0.64" STUDY_ID="STD-Abd-El_x002d_Aal-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="12.282960164643804"/>
<IV_DATA CI_END="1.4923952094928756" CI_START="0.2186282779170212" EFFECT_SIZE="0.5712090638488149" ESTIMABLE="YES" ESTIMATE="-0.56" LOG_CI_END="0.17388384630945836" LOG_CI_START="-0.6602936660411004" LOG_EFFECT_SIZE="-0.24320490986582102" MODIFIED="2010-04-07 14:33:00 +0200" MODIFIED_BY="[Empty name]" ORDER="4" SE="0.49" STUDY_ID="STD-Krischer-1991" TOTAL_1="0" TOTAL_2="0" WEIGHT="19.986692549699672"/>
<IV_DATA CI_END="1.7311569040456776" CI_START="0.5776483908899424" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.2383364321001597" LOG_CI_START="-0.2383364321001597" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-07 14:30:58 +0200" MODIFIED_BY="[Empty name]" ORDER="2" SE="0.28" STUDY_ID="STD-Taylor-2003_x002f_4" TOTAL_1="0" TOTAL_2="0" WEIGHT="49.758592158118425"/>
<IV_DATA CI_END="4.175279373869048" CI_START="0.5437959078241111" EFFECT_SIZE="1.5068177851128535" ESTIMABLE="YES" ESTIMATE="0.41" LOG_CI_END="0.6206855400520583" LOG_CI_START="-0.26456406489139184" LOG_EFFECT_SIZE="0.17806073758033322" MODIFIED="2010-04-07 14:24:25 +0200" MODIFIED_BY="[Empty name]" ORDER="3" SE="0.52" STUDY_ID="STD-Van-Eys-1981" TOTAL_1="0" TOTAL_2="0" WEIGHT="17.971755127538103"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="14.562820006847595" CI_END="1.0794141117105385" CI_START="0.9206961510807499" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9969014084021245" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="46" I2="58.79918863806093" I2_Q="53.531592584740345" ID="CMP-001.03" LOG_CI_END="0.03318809151125499" LOG_CI_START="-0.035883672388740406" LOG_EFFECT_SIZE="-0.0013477904387426943" METHOD="MH" MODIFIED="2014-11-13 16:10:04 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.02394360121907002" P_Q="0.07168052933590185" P_Z="0.9390299350508187" Q="8.607998901822594" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2050053817217592" TOTALS="SUB" TOTAL_1="347" TOTAL_2="337" WEIGHT="500.0" Z="0.07648916342914845">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>No chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chemotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no chemotherapy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0843320152380427" CI_START="0.9222267589143078" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.03516228064163232" LOG_CI_START="-0.03516228064163234" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 13:36:31 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="21" WEIGHT="100.0" Z="0.0">
<NAME>Alopecia grade 3</NAME>
<DICH_DATA CI_END="1.0843320152380427" CI_START="0.9222267589143078" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.03516228064163232" LOG_CI_START="-0.03516228064163234" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 13:36:31 +0200" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.041308995409982285" STUDY_ID="STD-Abd-El_x002d_Aal-2005" TOTAL_1="27" TOTAL_2="21" VAR="0.0017064331017819373" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3024337127164092" CI_START="0.4644676083692998" DF="0" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.11475562914311042" LOG_CI_START="-0.3330445679932465" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2012-04-29 20:03:13 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3393640078501411" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="21" WEIGHT="100.0" Z="0.9554226664162332">
<NAME>Reduction in intelligence quotient (IQ)</NAME>
<DICH_DATA CI_END="1.3024337127164092" CI_START="0.4644676083692998" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.11475562914311042" LOG_CI_START="-0.3330445679932465" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2010-04-07 14:41:46 +0200" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.2630400524446215" STUDY_ID="STD-Abd-El_x002d_Aal-2005" TOTAL_1="27" TOTAL_2="21" VAR="0.0691900691900692" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="24.90543678553403" CI_START="1.2787909385073033" DF="0" EFFECT_SIZE="5.643478260869566" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="1.3962941626869043" LOG_CI_START="0.10679955020661087" LOG_EFFECT_SIZE="0.7515468564467576" MODIFIED="2012-04-29 20:03:19 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.022334920693318314" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="118" WEIGHT="100.0" Z="2.2846233820188995">
<NAME>Severe infections</NAME>
<DICH_DATA CI_END="24.90543678553403" CI_START="1.2787909385073033" EFFECT_SIZE="5.643478260869565" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.3962941626869043" LOG_CI_START="0.10679955020661087" LOG_EFFECT_SIZE="0.7515468564467576" MODIFIED="2010-04-07 14:42:55 +0200" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.7574555184722015" STUDY_ID="STD-Evans-1990" TOTAL_1="115" TOTAL_2="118" VAR="0.5737388624639915" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.452539765870084" CI_START="0.20084362261859418" DF="0" EFFECT_SIZE="0.5401234567901234" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.16212803081214014" LOG_CI_START="-0.6971419538527757" LOG_EFFECT_SIZE="-0.2675069615203177" MODIFIED="2014-11-13 16:09:24 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.22233317426453736" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="1.2203475497820968">
<NAME>Haematological toxicity grade 3 or 4</NAME>
<DICH_DATA CI_END="1.452539765870084" CI_START="0.20084362261859418" EFFECT_SIZE="0.5401234567901234" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.16212803081214014" LOG_CI_START="-0.6971419538527757" LOG_EFFECT_SIZE="-0.2675069615203177" MODIFIED="2010-04-28 13:28:36 +0200" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.5047394424471945" STUDY_ID="STD-Krischer-1991" TOTAL_1="36" TOTAL_2="35" VAR="0.25476190476190474" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7578008070919675" CI_END="12.98313106809605" CI_START="0.43349118988443236" DF="2" EFFECT_SIZE="2.3723559882813747" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="1.1133794414331557" LOG_CI_START="-0.36301972453945874" LOG_EFFECT_SIZE="0.3751798584468485" MODIFIED="2014-11-13 16:10:04 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6846139542026675" P_Z="0.3191894600269516" STUDIES="3" TAU2="0.0" TOTAL_1="142" TOTAL_2="142" WEIGHT="100.00000000000001" Z="0.9961249331866643">
<NAME>Treatment-related mortality</NAME>
<DICH_DATA CI_END="14.944009270821828" CI_START="0.06325049939765828" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.174467128309567" LOG_CI_START="-1.1989360411435903" LOG_EFFECT_SIZE="-0.012234456417011635" MODIFIED="2010-04-16 13:05:58 +0200" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="1.3941487702719513" STUDY_ID="STD-Krischer-1991" TOTAL_1="36" TOTAL_2="35" VAR="1.9436507936507939" WEIGHT="38.69586385586231"/>
<DICH_DATA CI_END="71.87151794030787" CI_START="0.1224864157561265" EFFECT_SIZE="2.967032967032967" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8565568173367528" LOG_CI_START="-0.9119120736609652" LOG_EFFECT_SIZE="0.4723223718378937" MODIFIED="2010-04-16 13:06:07 +0200" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="1.6262123307140874" STUDY_ID="STD-Taylor-2003_x002f_4" TOTAL_1="90" TOTAL_2="89" VAR="2.6445665445665445" WEIGHT="28.439914529273935"/>
<DICH_DATA CI_END="108.38446736062465" CI_START="0.2881259138222898" EFFECT_SIZE="5.588235294117647" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.034967047673633" LOG_CI_START="-0.5404176798524856" LOG_EFFECT_SIZE="0.7472746839105738" MODIFIED="2010-04-29 11:15:21 +0200" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="1.5127937373088463" STUDY_ID="STD-Van-Eys-1981" TOTAL_1="16" TOTAL_2="18" VAR="2.288544891640867" WEIGHT="32.86422161486377"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-11-13 16:10:41 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Treatment including reduced-dose radiotherapy (RT) and chemotherapy versus treatment including standard-dose RT</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="2.9352367513975413" CI_START="0.805100540043536" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="1.5372575235482815" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.4676431364793008" LOG_CI_START="-0.09414988204250421" LOG_DATA="YES" LOG_EFFECT_SIZE="0.1867466272183983" MODIFIED="2011-01-21 11:12:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.19256441626889645" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.303030303030303">
<NAME>Event-free survival/disease-free survival (EFS/DFS)</NAME>
<GROUP_LABEL_1>Reduced RT+chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard RT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours reduced RT+chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard RT</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.9352367513975413" CI_START="0.805100540043536" EFFECT_SIZE="1.5372575235482815" ESTIMABLE="YES" ESTIMATE="0.43" LOG_CI_END="0.4676431364793008" LOG_CI_START="-0.09414988204250421" LOG_EFFECT_SIZE="0.1867466272183983" MODIFIED="2010-04-28 13:54:58 +0200" MODIFIED_BY="[Empty name]" ORDER="20" SE="0.33" STUDY_ID="STD-Bailey-1995-RTvslowRT_x002f_CT" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-11-17 12:04:15 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flow diagram CR Medullo Michiels et al.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-11-17 12:04:15 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow diagram of study selection</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAv4AAAN6CAYAAAD2M03DAAB5PElEQVR42uzdLY8lSZag4YIDk+2Q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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-11-17 12:04:15 +0100" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.1 Event-free survival/disease-free survival (EFS/DFS).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwMAAAHwCAMAAADNZUOPAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-11-17 12:04:15 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.2 Overall survival.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuQAAACwCAMAAABw+oufAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-11-17 12:04:15 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.3 Adverse effects.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0IAAAKgCAMAAACBez17AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-11-17 12:04:15 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-002.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Treatment including reduced-dose radiotherapy (RT) and chemotherapy versus treatment including standard-dose RT, outcome: 2.1 Event-free survival/disease-free survival (EFS/DFS).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxYAAACACAMAAAChtw9WAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-11-13 15:54:52 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-11-13 15:54:36 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-10-07 14:21:57 +0200" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-13 15:54:36 +0100" MODIFIED_BY="[Empty name]">
<P>(1) For <B>medulloblastoma</B>, we used the following subject headings and text words for searching title, abstract or keywords in clinical trials:</P>
<P>medulloblastoma OR medulloblastomas OR circumscribed arachnoidal cerebellar sarcoma OR desmoplastic medulloblastoma OR desmoplastic medulloblastomas OR childhood medulloblastoma OR childhood medulloblastomas OR medullomyoblastoma OR medullomyoblastomas OR melanocytic medulloblastoma OR melanocytic medulloblastomas OR medulloblast* OR medullomyoblast* OR large cell medulloblastoma OR large cell medulloblastomas OR brain neoplasm OR brain neoplasms OR intracranial neoplasm OR intracranial neoplasms OR cerebellar neoplasm OR cerebellar neoplasms OR brain tumor OR brain tumors OR cerebellar tumors OR cerebellar tumor OR primitive neuroepithelial tumor OR primitive neuroepithelial tumors OR primitive neuroectodermal tumor OR primitive neuroectodermal tumors OR primitive neuroepithelial neoplasm OR primitive neuroepithelial neoplasms OR primitive neuroectodermal neoplasms OR primitive neuroectodermal neoplasm OR PNET OR PNETs OR cerebral primitive neuroectodermal tumor OR ependymoblastoma OR ependymoblastomas OR ependymoblast* OR medulloepithelioma OR medulloepitheliomas OR medulloepitheliom* OR spongioblastoma OR spongioblastomas OR spongioblast* OR germ cell neoplasm OR embryonal neoplasm OR large cell anaplastic medulloblastoma OR large cell anaplastic medulloblastomas OR nodular desmoplastic medulloblastoma OR nodular desmoplastic medulloblastomas</P>
<P>(2) For <B>survival</B>, we used the following subject headings and text words for searching title, abstract or keywords in clinical trials:</P>
<P>survival OR survival rate OR survival rates OR cumulative survival rate OR cumulative survival rates OR survivorship OR mean survival time OR mean survival times OR survival time OR surviv* OR median survival time OR median survival times OR overall survival OR survival analysis OR survival analyses OR disease-free survival OR disease free survival OR event-free survival OR event-free survivals OR event free survival OR progression-free survival OR progression free survival OR progression-free survivals OR event-free OR event free OR progression free OR progression-free OR time to progression OR treatment outcome OR treatment effectiveness OR treatment efficacy OR neoplasm recurrence OR neoplasm recurrences OR disease-free survivals OR disease free survivals OR event free survivals OR progression free survivals OR treatment failure</P>
<P>(3) For <B>chemotherapy</B>, we used the following subject headings and text words for searching title, abstract or keywords in clinical trials:</P>
<P>chemotherapy OR chemotherapies OR chemotherap* OR antineoplastic protocol OR antineoplastic protocols OR cancer treatment protocols OR cancer treatment protocol OR antineoplastic combined chemotherapy protocols OR antineoplastic drug combinations OR antineoplastic drug combination OR anticancer drug combinations OR anticancer drug combination OR combined antineoplastic agents OR antineoplastic combined chemotherapy regimens OR antineoplastic chemotherapy protocols OR antineoplastic chemotherapy protocol OR cancer chemotherapy protocols OR cancer chemotherapy protocol</P>
<P>(4) For <B>children</B>, we used the following subject headings and text words for searching title, abstract or keywords in clinical trials:</P>
<P>infant OR infan* OR child OR child* OR schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen* OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* OR puberty OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school* OR elementary school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy</P>
<P>Finally, searches were combined as (1) AND (2) AND (3) AND (4).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-11-13 15:54:46 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-10-07 14:21:30 +0200" MODIFIED_BY="[Empty name]">MEDLINE/PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-13 15:54:46 +0100" MODIFIED_BY="[Empty name]">
<P>(1) For <B>medulloblastoma</B>, we used the following MeSH headings and text words:</P>
<P>medulloblastoma OR medulloblastomas OR circumscribed arachnoidal cerebellar sarcoma OR desmoplastic medulloblastoma OR desmoplastic medulloblastomas OR childhood medulloblastoma OR childhood medulloblastomas OR medullomyoblastoma OR medullomyoblastomas OR melanocytic medulloblastoma OR melanocytic medulloblastomas OR medulloblast* OR medullomyoblast* OR large cell medulloblastoma OR large cell medulloblastomas OR brain neoplasm OR brain neoplasms OR intracranial neoplasm OR intracranial neoplasms OR cerebellar neoplasm OR cerebellar neoplasms OR brain tumor OR brain tumors OR cerebellar tumors OR cerebellar tumor OR primitive neuroepithelial tumor OR primitive neuroepithelial tumors OR primitive neuroectodermal tumor OR primitive neuroectodermal tumors OR primitive neuroepithelial neoplasm OR primitive neuroepithelial neoplasms OR primitive neuroectodermal neoplasms OR primitive neuroectodermal neoplasm OR PNET OR PNETs OR cerebral primitive neuroectodermal tumor OR ependymoblastoma OR ependymoblastomas OR ependymoblast* OR medulloepithelioma OR medulloepitheliomas OR medulloepitheliom* OR spongioblastoma OR spongioblastomas OR spongioblast* OR germ cell neoplasm OR embryonal neoplasm OR large cell anaplastic medulloblastoma OR large cell anaplastic medulloblastomas OR nodular desmoplastic medulloblastoma OR nodular desmoplastic medulloblastomas</P>
<P>(2) For <B>survival</B>, we used the following MeSH headings and text words:</P>
<P>survival OR survival rate OR rate, survival OR rates, survival OR survival rates OR cumulative survival rate OR cumulative survival rates OR rate, cumulative survival OR rates, cumulative survival OR survival rate, cumulative OR survival rates, cumulative OR survivorship OR mean survival time OR mean survival times OR survival time, mean OR survival times, mean OR time, mean survival OR times, mean survival OR survival time OR surviv* OR median survival time OR median survival times OR survival time, median OR survival times, median OR time, median survival OR times, median survival OR overall survival OR analysis, survival OR analyses, survival OR survival analysis OR survival analyses OR disease-free survival OR disease free survival OR survival, disease-free OR disease-free survivals OR survival, disease free OR survivals, disease-free OR event-free survival OR event-free survivals OR event free survival OR survival, event-free OR survivals, event-free OR progression-free survival OR progression free survival OR progression-free survivals OR survival, progression-free OR survivals, progression-free OR event-free OR event free OR progression free OR progression-free OR time to progression OR treatment outcome OR treatment effectiveness OR treatment efficacy OR neoplasm recurrence OR neoplasm recurrences</P>
<P>(3) For <B>chemotherapy</B>, we used the following MeSH headings and text words:</P>
<P>chemotherapy OR chemotherapies OR chemotherap* OR antineoplastic protocol OR antineoplastic protocols OR protocol, antineoplastic OR protocols, antineoplastic OR cancer treatment protocols OR cancer treatment protocol OR protocol, cancer treatment OR protocols, cancer treatment OR treatment protocol, cancer OR treatment protocols, cancer OR antineoplastic combined chemotherapy protocols OR antineoplastic agents, combined OR agent, combined antineoplastic OR agents, combined antineoplastic OR antineoplastic agent, combined OR combined antineoplastic agent OR antineoplastic drug combinations OR antineoplastic drug combination OR combinations, antineoplastic drug OR drug combination, antineoplastic OR anticancer drug combinations OR anticancer drug combination OR drug combination, anticancer OR drug combinations, anticancer OR Combined antineoplastic agents OR antineoplastic combined chemotherapy regimens OR drug combinations, antineoplastic OR antineoplastic chemotherapy protocols OR antineoplastic chemotherapy protocol OR chemotherapy protocol, antineoplastic OR protocol, antineoplastic chemotherapy OR protocols, antineoplastic chemotherapy OR cancer chemotherapy protocols OR cancer chemotherapy protocol OR chemotherapy protocol, cancer OR chemotherapy protocols, cancer OR protocol, cancer chemotherapy OR protocols, cancer chemotherapy OR chemotherapy protocols, antineoplastic</P>
<P>(4) For <B>children</B>, we used the following MeSH headings and text words:</P>
<P>infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies OR neonat* OR child OR child* OR schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen* OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* OR puberty OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school* OR elementary school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy OR schools, nursery OR infant, newborn</P>
<P>(5) For identifying <B>RCTs</B> <B>and CCTs</B>, we used the highly sensitive search strategy as described in the Cochrane <I>Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>).</P>
<P>Finally, searches were combined as (1) AND (2) AND (3) AND (4) AND (5).</P>
<P>[RCT: randomised controlled trial; CCT: controlled clinical trial].</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-11-13 15:54:52 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-10-07 14:21:42 +0200" MODIFIED_BY="[Empty name]">EMBASE/Ovid search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-13 15:54:52 +0100" MODIFIED_BY="[Empty name]">
<P>(1) For <B>medulloblastoma</B>, we used the following Emtree terms and text words:</P>
<P>1. (medulloblastoma or medulloblastomas or circumscribed arachnoidal cerebellar sarcoma or desmoplastic medulloblastoma or desmoplastic medulloblastomas or childhood medulloblastoma or childhood medulloblastomas or medullomyoblastoma or medullomyoblastomas or melanocytic medulloblastoma or melanocytic medulloblastomas or medulloblast$ or medullomyoblast$ or large cell medulloblastoma or large cell medulloblastomas or brain neoplasm or brain neoplasms or intracranial neoplasm or intracranial neoplasms or cerebellar neoplasm or cerebellar neoplasms or brain tumor or brain tumors or cerebellar tumors or cerebellar tumor or primitive neuroepithelial tumor or primitive neuroepithelial tumors or primitive neuroectodermal tumor or primitive neuroectodermal tumors or primitive neuroepithelial neoplasm or primitive neuroepithelial neoplasms or primitive neuroectodermal neoplasms or primitive neuroectodermal neoplasm or PNET or PNETs or cerebral primitive neuroectodermal tumor or ependymoblastoma or ependymoblastomas or ependymoblast$ or medulloepithelioma or medulloepitheliomas or medulloepitheliom$ or spongioblastoma or spongioblastomas or spongioblast$ or germ cell neoplasm or embryonal neoplasm).mp.</P>
<P>2. (large cell anaplastic medulloblastoma or large cell anaplastic medulloblastomas or nodular desmoplastic medulloblastoma or nodular desmoplastic medulloblastomas).mp.</P>
<P>3. 1 or 2</P>
<P>4. medulloblastoma/ or circumscribed arachnoidal cerebellar sarcoma/</P>
<P>5. desmoplastic medulloblastoma/</P>
<P>6. cerebellum tumor/ or intracranial tumor/</P>
<P>7. Neuroepithelioma/</P>
<P>8. Neuroectoderm Tumor/</P>
<P>9. EPENDYMOBLASTOMA/</P>
<P>10. spongioblastoma/ or medullomyoblastoma/</P>
<P>11. or/4-10</P>
<P>12. 3 or 11</P>
<P>(2) For <B>survival</B>, we used the following Emtree terms and text words:</P>
<P>1. (survival or survival rate or survival rates).mp.</P>
<P>2. (cumulative survival rate or cumulative survival rates).mp.</P>
<P>3. survivorship.mp.</P>
<P>4. (mean survival time or mean survival times).mp.</P>
<P>5. (survival time or surviv$).mp.</P>
<P>6. (median survival time or median survival times).mp.</P>
<P>7. overall survival.mp.</P>
<P>8. (survival analysis or survival analyses).mp.</P>
<P>9. (disease-free survival or disease free survival).mp.</P>
<P>10. (disease-free survivals or disease free survivals).mp.</P>
<P>11. (event-free survival or event-free survivals or event free survival or event free survivals).mp.</P>
<P>12. (progression-free survival or progression free survival or progression-free survivals or progression free survivals).mp.</P>
<P>13. (survival period or survival probability).mp.</P>
<P>14. (event-free or event free or progression free or progression-free).mp.</P>
<P>15. (time to progression or treatment outcome or treatment effectiveness or treatment efficacy).mp.</P>
<P>16. (neoplasm recurrence or neoplasm recurrences).mp.</P>
<P>17.(cancer recurrence or cancer recurrences or cancer recidive or cancer remission).mp.</P>
<P>18. (therapy outcome or therapeutic efficacy).mp.</P>
<P>19. or/1-18</P>
<P>20. SURVIVAL RATE/ or SURVIVAL/ or SURVIVAL TIME/</P>
<P>21. Treatment Outcome/</P>
<P>22. Cancer survival/ or Cancer Recurrence/</P>
<P>23. or/20-22</P>
<P>24. 19 or 23</P>
<P>(3) For <B>chemotherapy</B>, we used the following Emtree terms and text words:</P>
<P>1. (chemotherapy or chemotherapies or chemotherap$ or antineoplastic protocol or antineoplastic protocols or cancer treatment protocols or cancer treatment protocol or antineoplastic combined chemotherapy protocols or antineoplastic drug combinations or antineoplastic drug combination or anticancer drug combinations or anticancer drug combination or combined antineoplastic agents or antineoplastic combined chemotherapy regimens or antineoplastic chemotherapy protocols or antineoplastic chemotherapy protocol or cancer chemotherapy protocols or cancer chemotherapy protocol).mp.</P>
<P>2. (anticancer chemotherapy or antineoplastic chemotherapy or cancer multichemotherapy or cancer polychemotherapy).mp.</P>
<P>3. chemotherapy/ or combination chemotherapy/</P>
<P>4. cancer combination chemotherapy/</P>
<P>5. cancer chemotherapy/ or antineoplastic agent/</P>
<P>6. clinical protocol/</P>
<P>7. or/1-6</P>
<P>(4) For <B>children</B>, we used the following Emtree terms and text words:</P>
<P>1. infant/ or infancy/ or newborn/ or baby/ or child/ or preschool child/ or school child/</P>
<P>2. adolescent/ or juvenile/ or boy/ or girl/ or puberty/ or prepuberty/ or pediatrics/</P>
<P>3. primary school/ or high school/ or kindergarten/ or nursery school/ or school/</P>
<P>4. or/1-3</P>
<P>5. (infant$ or (newborn$ or new born$) or (baby or baby$ or babies) or neonate$).mp.</P>
<P>6. (child$ or (school child$ or schoolchild$) or (school age$ or schoolage$) or (pre school$ or preschool$)).mp.</P>
<P>7. (kid or kids or toddler$ or adoles$ or teen$ or boy$ or girl$).mp.</P>
<P>8. (minors$ or (under ag$ or underage$) or juvenil$ or youth$).mp.</P>
<P>9. (puber$ or pubescen$ or prepubescen$ or prepubert$).mp.</P>
<P>10. (pediatric$ or paediatric$ or peadiatric$).mp.</P>
<P>11. (school or schools or (high school$ or highschool$) or primary school$ or nursery school$ or elementary school or secondary school$ or kindergar$).mp.</P>
<P>12. or/5-11</P>
<P>13. 4 or 12</P>
<P>(5) For <B>RCTs and CCTs</B>, we used the following Emtree terms and text words:</P>
<P>1. Clinical Trial/</P>
<P>2. Controlled Study/</P>
<P>3. Randomized Controlled Trial/</P>
<P>4. Double Blind Procedure/</P>
<P>5. Single Blind Procedure/</P>
<P>6. Comparative Study/</P>
<P>7. RANDOMIZATION/</P>
<P>8. Prospective Study/</P>
<P>9. PLACEBO/</P>
<P>10. Phase 2 Clinical Trial/</P>
<P>11. phase 3 clinical study.mp.</P>
<P>12. phase 4 clinical study.mp.</P>
<P>13. Phase 3 Clinical Trial/</P>
<P>14. Phase 4 Clinical Trial/</P>
<P>15. or/1-14</P>
<P>16. allocat$.mp.</P>
<P>17. blind$.mp.</P>
<P>18. control$.mp.</P>
<P>19. placebo$.mp.</P>
<P>20. prospectiv$.mp.</P>
<P>21. random$.mp.</P>
<P>22. ((singl$ or doubl$ or trebl$ or tripl$) and (blind$ or mask$)).mp.</P>
<P>23. (versus or vs).mp.</P>
<P>24. (randomized controlled trial$ or randomised controlled trial$).mp.</P>
<P>25. controlled clinical trial$.mp.</P>
<P>26. clinical trial$.mp.</P>
<P>27. or/16-26</P>
<P>28 Human/</P>
<P>29. Nonhuman/</P>
<P>30. ANIMAL/</P>
<P>31. Animal Experiment/</P>
<P>32. or/29-31</P>
<P>33. 32 not 28</P>
<P>34. (15 or 27) not 33</P>
<P>Finally, searches were combined as (1) AND (2) AND (3) AND (4) AND (5).</P>
<P>[mp: title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name; RCT: randomised controlled trial; CCT: controlled clinical trial]. </P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="AFF_B052A22382E26AA200D5E26BD0448571_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="B052A22382E26AA200D5E26BD0448571"><ADDRESS><ORGANISATION>University Paris Descartes</ORGANISATION><CITY>Sorbonne Paris Cité</CITY><COUNTRY CODE="FR">France</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>